RESMED INC (RMD) — Council Assessment

🟡 WATCH · Score 66/100 · medium confidence

High-quality, net-cash sleep-apnea franchise trading at a fair-but-not-cheap multiple with a thin margin of safety and an unquantified ventilator recall overhang.

As of 2026-10-19. 19 lenses weighed in, 0 abstained. Sources: 11 filings, 80 news.

360 narrative — news & sentiment digest

ResMed Inc. (RMD) – Investment Brief

Recent Developments

• Q4 FY2026 earnings scheduled for August 6, 2026 (announced end of June).
• MatrixCare sale announced (July 2026): Needham maintained "Hold" rating on the news.
• Ventilator recall headwinds: UBS flagged ventilator issues as a cloud over FY27 guidance (July 2026).
• Dividend increase: Company raised dividend; ChartMill and Sahm noted sustainable payout structure.
• Record free cash flow: $1.7 billion FCF achieved, despite stock trading down 30% from peak (July 2026 reporting).

Management Commentary (Earnings Call)

No full earnings call transcript provided in the material. The available coverage references a Q3 2026 earnings summary (April 2026) but does not include management quotes or guidance detail. Without a transcript, cannot assess tone, forward guidance specifics, or management candor on key challenges (ventilator recalls, MatrixCare integration).

Bull Narrative

• Strong cash generation: $1.7B FCF hit (mid-2026), supporting dividends and buybacks.
• Valuation dislocation: Multiple sources (GuruFocus, Yahoo Finance, TIKR) flagged the stock as undervalued despite 20–30% YTD declines. "Cheap even as market stays cautious" (Yahoo Finance, July 2026).
• Quality fundamentals: ChartMill highlighted strong profitability, cash conversion, and a sustainable dividend yield built on solid financials.
• Institutional accumulation: State Street, Deutsche Bank, Mitsubishi UFJ Asset Management, and California Teachers' Retirement System all increased holdings (June–September 2026).
• RBC upgrade (September 15, 2026): RBC Capital Markets upgraded RMD, contradicting an earlier downgrade in mid-July.
• OSA market expansion: Obstructive sleep apnea market remains a growth driver (Yahoo Finance, June 2026).

Bear Narrative

• Ventilator recall uncertainty: UBS explicitly cited ventilator issues as clouding FY27 earnings visibility (July 2026). Scope and financial impact not fully disclosed in available material.
• Stock down 20–30% YTD: Sustained underperformance vs. broad market through mid-2026, suggesting underlying concern beyond valuation.
• Analyst churn and conflicting signals: RBC downgraded mid-July, then upgraded September 15—signaling uncertainty. Needham held "Hold" on MatrixCare sale news.
• Insider selling: CEO sold ~$1M in stock in August 2026; counsel surrendered shares for RSU tax withholding (June 2026). Not necessarily bearish but lacks confidence signal.
• Guidance void: No forward guidance detail available in material; MatrixCare divestiture timing and integration risks unclear.

Retail Sentiment

Limited retail forum discussion in material. TradingView and Simply Wall Street articles pose neutral/cautious questions ("Is this the right time to retain?" "Stock forecast & analyst predictions") but do not capture active community sentiment. Tone appears mixed-to-cautious, reflective of technical weakness and headline risks.

Caveats

• No earnings call transcript: Critical gap. Cannot assess management's specific outlook, margin trajectory, capex plans, or candor on ventilator recall scope and remediation costs.
• Thin detail on MatrixCare divestiture: Sale announced in July; rationale, buyer, proceeds, and integration timeline not disclosed in material.
• Ventilator recall scope unclear: UBS mentioned it clouds FY27; no regulatory filings, financial reserve estimates, or recall scope provided.
• Analyst price target inconsistency: Mid-August cut to $258.47 (14% upside from ~$226) after July downgrade—suggests moving target.
• Insider transactions routine but sparse: A few share sales/RSU withholdings noted; insufficient to draw strong conclusions.
• No guidance update in material: Last concrete forward data point is Q3 2026 summary (April 2026); no Q4 or FY27 guidance visible.

---

Summary for Council: RMD trades at a 20–30% discount to peak, backed by record FCF and solid fundamentals, yet faces a near-term overhang from ventilator recalls and MatrixCare divestiture execution risk. Recent analyst upgrades and institutional buying suggest selective confidence, but the absence of management guidance and unclear scope of the ventilator issue warrant caution. Monitor Q4 earnings (due August 6) for clarity on recall liability, MatrixCare proceeds, and FY27 guidance before committing.

Bull case

ResMed is a textbook compounder: ROIC ~21% vs. ~8% WACC (a ~1,300bps spread), 33.4% operating margins, 29% FCF margins, and FCF that grew from $216M (FY2022) to $1.65B (FY2026). The balance sheet is fortress-grade — net cash of ~$1.07B, debt/equity 0.06 — and the moat (AirView/myAir connected-device data, consumable mask replenishment, regulatory clearance, payer/physician workflow lock-in) is durable and arguably AI-enhanced. The DCF pegs base intrinsic value at $298 vs. $235.50, ~27% upside, with implied expectations only requiring ~8-9% FCF growth — below the demonstrated 10.2% CAGR. The quality bench (Smith 82, Munger/Akre/Buffett/Fisher 78, Mauboussin 76) is broadly bullish.

Bear case

The valuation bench is far less enthusiastic. Greenwald's EPV is ~$140-143/share — the price sits ~65% above a no-growth franchise value, meaning you are paying heavily for growth. The DCF leans on terminal value for 79.2% of EV, and the bear-case DCF ($233) is essentially at today's price, so there is no meaningful margin of safety. Druckenmiller flags a broken tape (-9% over 52wk, -15% from highs), decelerating growth, and a slight FCF decline in FY2026 ($1.649B vs $1.662B) — the second derivative is turning. Graham (P/E 22, P/B 5.1) and Lynch (PEG 2.16) both find it priced well above their bars. Near-term, the ventilator/mask recall is a genuine unquantified liability.

Dissent — where the council disagrees

The sharpest dissent comes from the value bench and Druckenmiller. Schloss (AVOID 28) and Greenwald (WATCH 62, EPV ~$140) argue the price embeds a large, speculative growth premium with no asset floor — this matters because the DCF-driven ~27% upside that the quality lenses lean on is, in Greenwald's framing, the exact growth-dependent valuation structure that hides errors. Druckenmiller (WATCH 52) names a broken tape and negative FCF second-derivative, directly undercutting the 'durable compounder' narrative. Even the bulls (Buffett, Munger, Akre, Mauboussin) explicitly note the bear-case DCF equals the current price and keep confidence at medium. The tension: only the valuation referee (74) lands it as a clear buy among the price-sensitive seats, while five value/risk lenses say Watch and one says Avoid. The forensic short-seller is clean (PASS 72), so this is a valuation/entry-point debate, not an accounting one.

Key risks

• Ventilator/mask (Astral, magnets) recall: field safety notification accrual jumped ~10x from $4.8M (Jun 2025) to $45.7M (Jun 2026); ultimate scope unquantified and flagged by UBS as clouding FY27 guidance
• Thin margin of safety: bear-case DCF ($233) is essentially at the $235.50 price, and 79.2% of DCF value sits in terminal value
• Growth deceleration: revenue growth flat ~10% YoY with no acceleration; FCF declined slightly FY2025→FY2026 and FCF margin compressed from 32.3% to 29.2%
• GLP-1/obesity-drug threat to long-term OSA addressable market (raised by multiple lenses, speculative and not in the fact base)
• MatrixCare divestiture terms/proceeds and FY27 guidance undisclosed; no earnings call transcript available, creating a forward-visibility gap
• Short-term debt rose from $10M to $260M YoY (covered by cash but worth monitoring)

Catalysts

• Q4/FY2026 earnings clarity on recall remediation costs and FY27 guidance
• MatrixCare divestiture close with disclosed proceeds and capital-redeployment plan
• Accelerated buybacks given net cash and price below intrinsic value
• Resolution/bounding of the ventilator recall liability
• Continued institutional accumulation (State Street, Deutsche Bank, CalSTRS) and the September 2026 RBC upgrade signaling sentiment bottoming

DCF valuation (finance-expert model)

two-stage DCF, Gordon terminal value, CAPM-weighted WACC.

Intrinsic value: $298.18/share vs price $235.5 → +27% (bear $233.41 · base $298.18 · bull $390.98).

Step	Value
Base free cash flow	$1.6B
FCF growth (yrs 1-5)	10.2% (revenue CAGR)
WACC (β 0.769)	8.1%
Terminal growth	2.5%
PV of explicit FCF	$8.7B
PV of terminal (residual) value	$33.2B (79% of EV)
Enterprise value	$41.9B
less Net debt	$-1.1B
= Equity value	$43.0B
/ Shares (144M) = intrinsic/share	$298.18

Short-sell evaluation

🚫 AVOID SHORTING

This is a poor short. The forensic short-seller lens returned a clean PASS (72) — operating cash flow exceeds net income, FCF conversion is above 100%, non-GAAP adjustments are disclosed and contained, and there is no accrual-inflation or debt-wall pattern. A net-cash balance sheet, 21% ROIC, 33% margins, low 0.77 beta, and a durable regulated moat make this a dangerous name to be short. The only credible short angle is valuation (price ~65% above Greenwald EPV, PEG 2.16, thin DCF margin of safety) plus recall/GLP-1 overhangs — but overvaluation alone, on a cash-rich quality compounder with buybacks and institutional accumulation, is not enough to overcome the asymmetry and squeeze/re-rating risk.

Pros (the short could work)

• Trades ~65% above Greenwald's no-growth EPV (~$140-143) and bear-case DCF sits at the current price — minimal downside cushion if growth disappoints
• Decelerating growth and slightly negative FCF second derivative (FY2026 FCF below FY2025); FCF margin compressing
• Unquantified ventilator/mask recall liability (accrual up ~10x) and potential GLP-1 erosion of the OSA market as negative catalysts
• Broken tape — down ~9% over 52 weeks and ~15% off highs — momentum is not fighting a short

Cons (what kills the short)

• Clean forensic profile: OCF > net income, >100% FCF conversion, no accounting red flags (short-seller lens PASS 72)
• Fortress balance sheet: ~$1.07B net cash, debt/equity 0.06, 3.1x current ratio — no solvency pressure to catalyze a decline
• Durable moat and 21% ROIC with secular OSA tailwind; AI is more likely moat-enhancing than disruptive near-term
• Buybacks, a rising dividend, and active institutional accumulation plus a recent analyst upgrade create re-rating/squeeze risk
• Unlimited downside asymmetry on shorting a high-quality, low-beta compounder that is only modestly, not egregiously, overvalued

Council scorecard

Lens	School	Stance	Score	Conf
Terry Smith (Fundsmith)	quality	🟢 pass	82	high
Chuck Akre	quality	🟢 pass	78	medium
Warren Buffett	quality	🟢 pass	78	medium
Philip Fisher	growth	🟢 pass	78	medium
Charlie Munger	quality	🟢 pass	78	medium
Michael Mauboussin	quality	🟢 pass	76	medium
Valuation Referee (Damodaran-style)	referee	🟢 pass	74	medium
Ray Dalio	risk	🟢 pass	72	medium
AI & Disruption Referee (Christensen-style)	referee	🟢 pass	72	medium
Forensic Short-Seller (Chanos/Einhorn-style)	referee	🟢 pass	72	medium
Joel Greenblatt	value	🟡 watch	62	medium
Bruce Greenwald	value	🟡 watch	62	medium
Howard Marks	risk	🟡 watch	58	medium
Stanley Druckenmiller	risk	🟡 watch	52	medium
Benjamin Graham	value	🟡 watch	52	medium
Seth Klarman	value	🟡 watch	52	medium
Peter Lynch	growth	🟡 watch	52	medium
Paul Singer	value	🟡 watch	52	medium
Walter Schloss	value	🔴 avoid	28	high

Member reasoning

Terry Smith (Fundsmith) — 🟢 pass · 82/100 · high confidence

ResMed is a textbook Fundsmith-quality business: it sells essential medical devices (CPAP/ventilators) plus high-attachment consumables (masks, accessories) that generate recurring replacement demand, has a dominant franchise in obstructive sleep apnea with genuine switching costs and brand loyalty, and now produces extraordinary cash flows. The financials confirm this. ROIC of 21.3% and ROE of 23.1% (fundamentals block) are well above cost of capital and sustained across multiple years — this is not a single good year. Operating margin of 33.4% (10-K FY2026: GAAP income from operations $1.887B on revenue $5.653B) is both high and expanding; net margin of 26.9% likewise. Cash conversion is excellent: FCF of $1.650B in FY2026 versus net income of $1.523B gives a cash conversion ratio above 100%, exactly what Smith demands — profits backed by real cash, not accruals. This pattern holds across the history table: FCF jumped from $574M (FY2023) to $1.302B (FY2024) to $1.662B (FY2025) to $1.650B (FY2026), all corroborated in the filings. Capital intensity is light: capex was $156M in FY2026 (10-K period 2026-06-30), just 2.8% of revenue, leaving the vast majority of operating cash flow as genuine free cash. Balance sheet is fortress-grade: total debt reduced dramatically (from $1.441B in FY2023 to $668M in FY2025 per the 10-K filed 2025-08-08, and long-term debt of $399M plus short-term of $260M as of June 2026 per the 10-K filed 2026-08-13), net cash position of approximately $1.07B (valuation block: net debt = -$1.070B), debt-to-equity of just 0.06. Smith's leverage fear is completely absent here. Valuation: at $235.50, price-to-FCF of 20.4x equates to an FCF yield of ~4.9%. For a business compounding FCF at roughly 10% annually with near-zero leverage and dominant market share in a structurally growing category, this is a defensible — arguably attractive — price. The DCF (10-K assumptions validated) yields $298/share base case, 26.6% upside, with even the bear case of $233 essentially at current price. The two concerns that prevent a higher score: (1) Serial acquisitions — ResMed has been active (Noctrix Health acquired June 2026 for $335M per the 10-K filed 2026-08-13; VirtuOx acquisition noted in the 10-Q; MEDIFOX DAN referenced historically). Smith distrusts acquisition-led growth, and the SG&A line includes 'acquisition and portfolio review related expenses' as a recurring non-GAAP adjustment ($11.5M in FY2026, $2.0M in FY2025 per the 10-K filed 2026-08-13). Goodwill and intangibles are meaningful on the balance sheet. However, ResMed's core organic growth is genuine, and it has been paying down the acquisition debt rapidly — the balance sheet trajectory is in the right direction. (2) Field safety notifications — the 10-K filed 2026-08-13 shows field safety notification accruals of $45.7M (masks with magnets) and separate Astral device replacement costs, versus only $4.8M a year prior. This is a real cash cost and an operational execution risk. AI disruption risk is low-to-moderate: ResMed's AirSense devices generate large proprietary datasets on patient compliance (millions of patients connected), and the company has invested in AI-driven adherence tools. This is actually an AI-enhancing franchise rather than one at risk — data network effects deepen the moat. The bear risk would be AI-assisted diagnostics reducing referrals or home monitoring commoditising, but near-term this appears remote given regulatory barriers and clinical workflow dependencies. MatrixCare divestiture (narrative: sale announced July 2026) may further simplify the story and sharpen focus on the core Sleep and Breathing Health segment, which is directionally positive for a quality lens. Overall: a high-quality, cash-generative, lightly capitalised franchise in a structurally growing healthcare market, trading at a fair rather than cheap price, with manageable near-term headwinds.

Key points

• ROIC of 21.3% and ROE of 23.1% sustained over multiple years, well above cost of capital — Smith's primary screen passes (fundamentals block)
• Operating margin 33.4% in FY2026 ($1.887B operating income on $5.653B revenue, 10-K filed 2026-08-13); net margin 26.9% — pricing power and moat confirmed
• FCF of $1.650B exceeds net income of $1.523B in FY2026 — cash conversion above 100%, exactly Smith's requirement; pattern consistent across FY2023-FY2026 (history table)
• Capex only $156M in FY2026 (2.8% of revenue) — genuinely asset-light growth model (fundamentals block)
• Balance sheet nearly debt-free: net cash ~$1.07B, long-term debt reduced from $1.435B (FY2023) to $399M (FY2026) per 10-K filings — Smith's leverage fear is absent
• Price-to-FCF of ~20x equates to ~4.9% FCF yield for a ~10% FCF compounder — fair price for outstanding quality; DCF base case $298/share implies 27% upside (valuation block)
• Recurring consumables demand (masks, accessories) and connected device ecosystem create sticky, repeat-purchase revenue resistant to economic cycles
• AI enhances rather than threatens: proprietary patient compliance datasets and AI adherence tools deepen moat; regulatory and clinical barriers protect against disintermediation

Red flags

• Active acquisitions (Noctrix $335M, June 2026; VirtuOx, prior year) create Smith-style concern about roll-up discipline; acquisition-related expenses are a recurring non-GAAP add-back ($11.5M FY2026 per 10-K filed 2026-08-13)
• Field safety notification accruals surged to $45.7M at June 2026 vs $4.8M at June 2025 (10-K filed 2026-08-13) — masks with magnets and Astral device issues represent execution risk and real cash costs
• Ventilator recall scope and FY2027 financial impact not fully disclosed in the fact base (narrative notes UBS flagged this as clouding FY27 guidance) — data gap
• Goodwill and intangibles are material (customer relationships and developed technology on balance sheet, 10-Q filed 2026-05-01) — acquisition history means intangible-heavy book value
• Insider selling: CEO sold ~$1M in stock August 2026 (narrative) — minor signal but noted
• SG&A ratio ticked up to 19.8% of revenue in FY2026 from 19.3% in FY2025 (10-K filed 2026-08-13) — small but worth watching for operating leverage trajectory

Chuck Akre — 🟢 pass · 78/100 · medium confidence

ResMed exhibits the core attributes of an Akre-quality compounder. The three-legged stool holds up well, though not perfectly. Leg one (extraordinary business): RMD dominates the CPAP/sleep therapy market with genuine switching costs embedded in its connected-care ecosystem (AirSense devices feed data into cloud-connected myAir/AirView platforms), high recurring revenue from masks and accessories, and a capital-light model evidenced by FCF margins running at 29-32% in FY2024-FY2026 (per fundamentals history). ROIC at 21.3% and ROE at 23.1% (fundamentals block, FY2026) clear the ~20% threshold without leverage distortion — long-term debt of $399M against $6.6B equity yields a debt-to-equity of just 0.06 (10-K filed 2026-08-13), so returns are genuine franchise economics, not financial engineering. Leg two (management skill and integrity): The capital allocation record is largely clean — debt has been systematically paid down from $1.44B (FY2023, per 10-K filed 2024-08-09) to $399M long-term (FY2026, 10-K filed 2026-08-13), while FCF has compounded from $216M in FY2022 to $1.65B in FY2026 (fundamentals history). The Noctrix Health acquisition ($335M, completed June 1, 2026, per 10-K filed 2026-08-13) adds wearable therapeutics, consistent with adjacency strategy. However, the narrative flags meaningful concerns: CEO sold ~$1M in stock (August 2026), ventilator recall issues cloud FY27 visibility (UBS flagged per narrative), and the MatrixCare divestiture rationale and proceeds remain undisclosed in available material. Field safety notification expenses jumped sharply — from $4.8M accrued at June 2025 to $45.7M at June 2026 (10-K filed 2026-08-13, accrued expenses table) — indicating recall liabilities that are real but not yet fully scoped. Non-GAAP framing is present but reconciliations are provided and appear straightforward (10-K filed 2026-08-13). Leg three (reinvestment runway): OSA remains massively underpenetrated globally; only ~20-25% of sufferers are diagnosed and treated (commonly cited, but NOT independently cited in this fact base — I flag this as unverified from fact base). The software segment (Residential Care) is being pruned (MatrixCare sale) to sharpen focus. FCF per share has compounded robustly as shares outstanding edged down from ~147M (FY2023) to ~144M (FY2026, fundamentals). Valuation: DCF intrinsic value per share of $298 vs. current price $235.50 (valuation block) implies ~27% upside; price-to-FCF of 20.4x (fundamentals) and P/E of 22x for a business compounding FCF at 10%+ is a reasonable GARP price. The bear case in sensitivity ($233) is essentially at current market price, flagging limited margin of safety if growth disappoints. AI disruption is not a primary near-term threat — RMD's connected-device ecosystem and clinical data network likely benefit from AI (better adherence analytics, remote monitoring optimization) more than they are disrupted, though AI-enabled diagnostics could lower barriers to sleep study alternatives and marginally expand the addressable market. The ventilator recall and FY27 guidance void are the main overhangs reducing confidence.

Key points

• ROIC 21.3%, ROE 23.1% with only 0.06 debt-to-equity — genuine franchise returns, not leverage-driven (fundamentals block, 10-K filed 2026-08-13)
• FCF compounded from $216M (FY2022) to $1.65B (FY2026) while share count declined modestly — FCF per share compounding is intact (fundamentals history)
• Long-term debt reduced from ~$1.44B (FY2023, 10-K filed 2024-08-09) to $399M (FY2026, 10-K filed 2026-08-13) — disciplined balance sheet management
• DCF intrinsic value $298 vs. $235.50 market price (~27% upside) with WACC 8.1% — reasonable GARP entry point if compounding thesis holds (valuation block)
• Capital-light model: capex only $156M against $1.81B operating cash flow in FY2026 (fundamentals), enabling high reinvestment or shareholder returns
• Operating margins 33.4% and FCF margins 29.2% in FY2026 demonstrate durable franchise economics (10-K filed 2026-08-13 and fundamentals)
• OSA market remains a long runway for global penetration growth — underpenetration thesis intact though fact base lacks specific penetration statistics

Red flags

• Field safety notification accruals jumped from $4.8M (June 2025) to $45.7M (June 2026) per 10-K filed 2026-08-13 — ventilator recall scope and FY27 financial impact not quantified in available material; UBS cited this as clouding FY27 guidance (narrative)
• MatrixCare divestiture announced July 2026 but proceeds, rationale, and timing not disclosed in available material — incomplete picture for assessing capital reallocation quality
• CEO sold ~$1M in stock (August 2026 per narrative) — not disqualifying but not a confidence signal at a time of operational headwinds
• No earnings call transcript available — cannot assess management candor on recall liability, FY27 guidance, or reinvestment pipeline; critical gap for Akre-style integrity assessment
• Restructuring charges of $21.7M in nine months ended March 31, 2026 (10-Q filed 2026-05-01) signal organizational disruption, following $64.2M in FY2024 restructuring (10-K filed 2025-08-08) — repeated restructuring is mildly inconsistent with a stable, predictable franchise
• Bear case DCF sensitivity ($233) is essentially at current market price, suggesting limited margin of safety if growth or margins disappoint (valuation block)

Warren Buffett — 🟢 pass · 78/100 · medium confidence

ResMed presents as a high-quality medical device franchise with many characteristics I look for: a durable moat in sleep-disordered breathing treatment, consistently high returns on equity and invested capital without meaningful leverage, strong and growing free cash flow conversion, and a balance sheet that is effectively a net-cash position. The business is understandable — it makes CPAP devices and masks, sells consumable accessories that patients must replace regularly, and supports those devices with proprietary software (myAir, AirView). The consumable/recurring element is structurally attractive: once a patient is fitted with a ResMed device, switching is functionally difficult given physician familiarity, insurer reimbursement pathways, and the clinical data ecosystem the company has built around connected devices. The 10-K filed 2026-08-13 confirms FY2026 revenue of $5.653 billion, operating income of $1.887 billion (33.4% GAAP operating margin), net income of $1.523 billion, and free cash flow of $1.650 billion — a 29.2% FCF margin. The multi-year trajectory is compelling: FCF has grown from $216 million in FY2022 to $1.650 billion in FY2026, a near eight-fold improvement, driven by the combination of revenue growth (~10% CAGR per fundamentals block) and substantial operating leverage following supply chain normalization post-pandemic. ROE of 23.1% and ROIC of 21.3% (fundamentals block) are achieved with a debt-to-equity ratio of only 0.06. Long-term debt is $399 million against cash of $1.469 billion — a net cash position of approximately $1.07 billion (per the valuation assumptions block). Interest coverage is essentially not a concern. This is the kind of fortress balance sheet I admire. Owner earnings are real: maintenance capex appears modest (total capex $156 million on $1.806 billion operating cash flow per fundamentals, or roughly 9% of operating cash flow), and the depreciation-adjusted free cash flow picture is sound. The two-stage DCF in the valuation block yields an intrinsic value of $298.18 per share against a current price of $235.50, suggesting roughly 27% upside with a bear-case floor of $233 — essentially at the current price. The WACC of 8.11% with a terminal growth rate of 2.5% strikes me as reasonable, not heroic. At a P/E of 22x and price-to-FCF of 20x, the stock is not a screaming bargain but is priced fairly for a business of this quality. I am not being asked to overpay for mediocrity. Several concerns temper my enthusiasm below a higher score. First, the ventilator recall issue referenced in the narrative (UBS flagged it as clouding FY27 guidance) is not quantified in the available filings. The 10-K for FY2026 discloses accrued field safety notification expenses of $45.7 million at June 30, 2026 (up from $4.8 million a year prior — a tenfold jump per the accrued expenses table in the 10-K filed 2026-08-13), which is a material increase and confirms the issue is real and being provisioned, though ultimate scope is unclear. Second, the Residential Care Software segment has produced recurring operating lease right-of-use asset impairments ($2.7 million in Q2 FY2026 per 10-Q filed 2026-01-30, another $2.7 million in Q3 per 10-Q filed 2026-05-01, and $4.1 million in FY2024 per the 10-K filed 2025-08-08) suggesting that segment is being rationalized — consistent with the narrative's reference to the MatrixCare divestiture announced July 2026. Divesting software assets is not inherently bad capital allocation, but I cannot assess the price received or buyer quality from the available material. Third, the Noctrix Health acquisition ($335 million, completed June 1, 2026 per the 10-K filed 2026-08-13) adds a wearable therapeutics platform whose economics are not yet proven. I am always cautious about acquisitions of unproven technology, even at relatively modest prices relative to ResMed's earnings power. Fourth, on AI disruption: ResMed's connected device platform (myAir, AirView) and its cloud-connected sleep data is actually AI-enhancing rather than AI-threatened. The data moat — millions of patient nights of sleep data — becomes more valuable as AI-driven diagnostics and adherence coaching improve. This is a tailwind, not a threat. The primary AI risk would be if a pure-software diagnostic layer were to disintermediate the device entirely, but given FDA regulation of CPAP therapy and the physical necessity of the device, I view this as low-probability over a 10-year horizon. On balance, ResMed earns a pass. The moat is real and defensible, the financial returns are exceptional, the balance sheet is conservative, and the price offers a modest but genuine margin of safety relative to a reasonable intrinsic value estimate. I would want more clarity on the ventilator recall liability and MatrixCare disposition terms before sizing a position aggressively, which keeps my confidence at medium rather than high.

Key points

• Durable moat: CPAP/mask ecosystem with high physician and insurer switching costs, proprietary connected-device data platform (myAir/AirView), and consumable mask replenishment cycle creating recurring revenue
• Exceptional financial returns: ROE 23.1%, ROIC 21.3% achieved with debt-to-equity of only 0.06 and net cash balance of ~$1.07B (10-K filed 2026-08-13, valuation block)
• Owner earnings are real and growing: FCF expanded from $216M in FY2022 to $1.650B in FY2026 with FCF margin of 29.2%; maintenance capex is modest at $156M vs. $1.806B operating cash flow
• Fair valuation with margin of safety: DCF intrinsic value of $298.18 vs. current price $235.50 (~27% upside); bear case $233 roughly equals today's price; P/FCF of 20x reasonable for this quality
• AI is a tailwind: ResMed's multi-million patient sleep-data asset and connected platform become more competitively valuable as AI-driven adherence and diagnostics improve; device cannot be disintermediated easily given FDA regulation
• Conservative balance sheet: $1.469B cash vs. $399M long-term debt; interest coverage not a concern; self-funding through downturns

Red flags

• Field safety notification accrual surged from $4.8M to $45.7M at June 30, 2026 (10-K filed 2026-08-13) — a tenfold increase confirming the ventilator/mask recall is being provisioned but ultimate financial scope remains unclear
• MatrixCare divestiture terms (buyer, proceeds, timing) not available in the fact base; cannot assess whether capital is being returned or redeployed wisely
• Noctrix Health acquisition ($335M, June 2026 per 10-K filed 2026-08-13) adds unproven wearable therapeutics; small relative to earnings power but represents speculative technology outside ResMed's core competency
• Recurring Residential Care Software segment lease impairments ($2.7M each in Q2 and Q3 FY2026) suggest ongoing rationalization costs and segment underperformance
• CEO insider selling (~$1M, August 2026 per narrative) is not conclusive but is not a confidence-building signal; no transcript available to assess management candor on recall scope or FY27 guidance
• No forward guidance available in fact base; recall liability and MatrixCare transition create near-term earnings visibility gap

Philip Fisher — 🟢 pass · 78/100 · medium confidence

ResMed passes the Fisher growth lens on most key criteria, though with some questions around the transition period and near-term headwinds. Revenue has compounded at ~10.2% over three years (revenue CAGR per fundamentals block), driven by a genuine expansion of the obstructive sleep apnea device and software markets rather than pure price. Operating margins of 33.4% (FY2026, per 10-K filed 2026-08-13) and FCF margins of ~29% are best-in-class, and the FCF trajectory from $216M in FY2022 to $1.65B in FY2026 is extraordinary — the kind of scale-driven earnings compounding Fisher prizes. The balance sheet is net-cash-positive ($1.47B cash vs. $399M long-term debt per 10-K FY2026), debt-to-equity a negligible 0.06, and ROIC of 21.3% signals that capital is being deployed at well above the cost of capital. The Noctrix Health acquisition (June 1, 2026, $335M for wearable sleep therapeutics, per 10-K FY2026 business combinations note) is consistent with a Fisher-approved expansion into adjacent clinical territory rather than financial engineering. The MatrixCare divestiture (per narrative digest) signals portfolio discipline — pruning non-core software rather than accumulating unrelated assets. On the product front, the sleep and breathing health segment continues to grow with recurring consumable mask revenue layered atop device sales, a classic Fisher-approved razor-and-blades model with high switching costs. R&D investment has been consistent, though precise R&D spend figures are not broken out in the excerpts available — this is a gap in the fact base. SG&A as a percentage of revenue was 19.8% in FY2026 vs. 19.3% in FY2025 (10-K filed 2026-08-13), a modest uptick that warrants watching but does not signal deterioration. The ventilator recall headwinds (UBS-cited per narrative, no filing detail on scope or reserve) are a genuine near-term concern — field safety notification accruals jumped to $45.7M vs. $4.8M the prior year (10-K FY2026, accrued expenses note), which is a significant increase in remediation cost. Restructuring charges of $21.7M in nine months ended March 31, 2026 (10-Q filed 2026-05-01) also reflect management actively reshaping the cost base — consistent with long-term orientation but creates near-term earnings noise. Candor is a moderate concern: narrative notes the absence of a full earnings call transcript, limiting scuttlebutt on management tone. Insider selling by CEO (~$1M, per narrative) is not alarming but not a confidence signal. Institutional accumulation by State Street, Deutsche Bank, and CALSTRS (narrative) provides partial scuttlebutt validation. AI/disruption risk: ResMed's connected device platform (AirView, myAir) with a 10+ billion nights of sleep data moat is actually an AI enabler rather than a target — proprietary datasets and embedded clinical workflows create durable differentiation. AI commoditization risk to the core CPAP/bilevel device is low given FDA regulatory barriers and payer reimbursement requirements; AI more plausibly accelerates early diagnosis and patient identification, expanding the addressable market. The primary risk is not AI displacement but rather recall scope, GLP-1/obesity drug impact on OSA prevalence (not mentioned in fact base, a question to verify), and whether organic growth can re-accelerate toward prior double-digit rates.

Key points

• Revenue CAGR of 10.2% over three years (fundamentals block), growing from $3.58B (FY2022) to $5.65B (FY2026) — sustained above-average organic growth in a structurally underpenetrated sleep health market
• Operating margin of 33.4% and FCF margin of 29.2% in FY2026 (10-K filed 2026-08-13) — exceptional profitability demonstrating pricing power and scale advantages
• FCF expanded from $216M (FY2022) to $1.65B (FY2026) — a 7.6x increase in four years reflecting operating leverage, exactly the earnings compounding Fisher prizes
• ROIC of 21.3% (fundamentals) far exceeds the WACC of 8.1% (valuation block), confirming high-quality capital allocation
• Net-cash balance sheet ($1.47B cash, $399M long-term debt per FY2026 10-K) enables acquisitions and R&D without dilutive equity raises
• Noctrix Health acquisition (June 2026, $335M per 10-K business combinations note) — clinically adjacent wearable therapeutics representing disciplined product-line extension
• MatrixCare divestiture (narrative) shows management willingness to prune non-core assets in favor of core franchise, consistent with long-term orientation
• DCF intrinsic value of $298/share vs. current price of $235.50 implies 26.6% upside (valuation block) — meaningful margin of safety for a Fisher-quality compounder
• Connected device platform with 10B+ nights of sleep data (narrative context) creates a defensible AI moat that accelerates rather than is threatened by machine learning advances
• Institutional buying by State Street, Deutsche Bank, CALSTRS (narrative) provides partial scuttlebutt validation of management quality

Red flags

• Field safety notification accruals surged to $45.7M vs. $4.8M prior year (10-K FY2026, accrued expenses note) — Astral ventilator recall scope and total liability unclear; UBS cited this as clouding FY27 visibility (narrative), representing genuine earnings uncertainty
• R&D spend as an absolute figure and as a percentage of revenue is not disclosed in the available excerpts — cannot confirm Fisher's criterion of consistent, productive R&D investment vs. peers; this is a material gap in the fact base
• No earnings call transcript available (narrative caveat) — limits assessment of management candor on ventilator recall remediation, MatrixCare divestiture rationale, and FY27 growth trajectory; Fisher heavily weights management communication quality
• SG&A rising slightly as a percentage of revenue (19.8% FY2026 vs. 19.3% FY2025 per 10-K filed 2026-08-13) warrants monitoring to confirm it does not reflect structural sales force inefficiency
• Restructuring charges of $21.7M in nine months ended March 2026 (10-Q filed 2026-05-01) signal workforce disruption; cumulative restructuring over FY2024-FY2026 suggests more organizational churn than a Fisher-ideal stable management culture
• GLP-1/obesity drug impact on OSA prevalence not mentioned in any filing or narrative — represents a potentially significant long-term market-size risk that is not addressable from this fact base and requires scuttlebutt verification
• CEO stock sale of ~$1M (August 2026, narrative) — not alarming in isolation but is absence of insider conviction at a point when management should be expressing confidence in the franchise

Charlie Munger — 🟢 pass · 78/100 · medium confidence

ResMed is precisely the kind of business Charlie Munger would find interesting: a dominant player in a growing, medically essential market (obstructive sleep apnea and respiratory therapy), with a durable moat rooted in clinical brand trust, proprietary device-and-software ecosystems, switching costs, and scale. The economics are genuinely high quality. Per the 10-K filed 2026-08-13, ROIC is 21.3% and ROE is 23.1% — comfortably above the 15% Munger bar. Operating margin is 33.4% and FCF margin reached 29.2% for FY2026 ($1.65B FCF on $5.65B revenue). The balance sheet is essentially pristine: long-term debt of $399M against cash of $1.47B (net cash position of roughly $1.07B per the valuation block), debt-to-equity of 0.06. Free cash flow conversion is excellent — earnings are clearly backed by cash, not accounting fiction. Revenue has compounded at ~10.2% over three years (per fundamentals block) and net income has grown from $779M in FY2022 to $1.52B in FY2026 — genuine compounding of owner earnings. The business is understandable: ResMed makes CPAP devices and masks, sells them through a recurring consumables stream (masks/accessories replaced regularly), and adds a software layer for care coordination. Unit economics are simple. The DCF (valuation block) yields an intrinsic value of $298/share vs. a $235.50 price — a ~27% discount, or roughly fair-to-modestly-cheap for a business of this quality. The price-to-FCF of 20.4x is not heroic for a compounder with 33% FCF margins and double-digit reinvestment returns. PEG of 2.16 is not cheap in isolation but is acceptable for a durable franchise. The inversion test: permanent capital impairment would require a structural collapse of the CPAP market (OSA affects hundreds of millions globally — not going away), a disruptive substitute technology displacing ResMed at scale, or catastrophic regulatory action. None of these appear imminent. The ventilator recall and MatrixCare divestiture create near-term noise but not existential risk. AI risk is moderate and two-sided: AI could enhance ResMed's remote monitoring and data analytics moat (more value to payers/providers), but could also accelerate commoditization of device hardware if algorithms commoditize diagnosis. On balance, ResMed's software layer and clinical data network are more likely enhanced than threatened by AI. Key concerns that prevent a higher score: (1) ventilator recall scope is genuinely unclear from this fact base — accrued field safety notification expenses jumped from $4.8M to $45.7M (10-K 2026-08-13), a tenfold increase, and the financial ceiling is unknown; (2) no earnings call transcript means management candor and FY27 guidance visibility are blind spots; (3) CEO sold ~$1M in stock per the narrative — minor but noted; (4) restructuring charges of $21.7M in the nine months to March 2026 (10-Q filed 2026-05-01) add a small recurring quality question; (5) the MatrixCare divestiture rationale and proceeds are undisclosed in this fact base, creating uncertainty about capital redeployment. Overall: a high-quality compounder available at a fair-to-modestly-cheap price. Munger would likely approve a position but size it carefully given the recall overhang.

Key points

• ROIC 21.3%, ROE 23.1%, FCF margin 29.2% — all well above the Munger 15% quality threshold (fundamentals block, 10-K 2026-08-13)
• Net cash balance sheet: $1.47B cash vs. $399M long-term debt; debt-to-equity of 0.06 — survives any plausible downturn (10-K 2026-08-13)
• FCF grew from $216M in FY2022 to $1.65B in FY2026 — genuine owner-earnings compounding over the cycle (fundamentals history block)
• Operating margin 33.4%; SG&A as % of revenue stable at ~19% — pricing power and scale economics intact (10-K 2026-08-13)
• DCF intrinsic value $298 vs. $235.50 price (~27% upside); price-to-FCF of 20.4x is a fair price for this quality, not a heroic multiple
• Moat is multi-layered: clinical brand trust, consumables recurring revenue stream, proprietary device-software ecosystem, scale manufacturing, and a growing care data network
• Business is simple and understandable: CPAP/ventilator devices + recurring masks + software; unit economics explainable in one paragraph
• AI more likely enhances than destroys the moat — remote monitoring and data analytics are additive to ResMed's platform value proposition

Red flags

• Field safety notification accrual jumped from $4.8M to $45.7M year-over-year (10-K 2026-08-13) — Astral ventilator recall financial ceiling is unknown and clouds FY27 earnings; this is the single most material near-term uncertainty
• No earnings call transcript in this fact base — cannot assess management candor, FY27 guidance, or remediation timeline for ventilator recall
• MatrixCare divestiture announced July 2026 per narrative — rationale, proceeds, and capital redeployment plan are undisclosed; unclear if this strengthens or dilutes the franchise
• Restructuring charges of $21.7M in nine months to March 2026 (10-Q 2026-05-01) — minor but recurring restructuring is a small accounting quality flag
• Noctrix acquisition ($335M, June 2026 per 10-K 2026-08-13) adds M&A integration risk to an already complicated near-term period; purchase price allocation is preliminary
• CEO share sale (~$1M, August 2026 per narrative) — individually immaterial but directionally worth monitoring

Michael Mauboussin — 🟢 pass · 76/100 · medium confidence

ResMed's ROIC of 21.3% against an estimated WACC of ~8.1% (per the DCF block) represents a spread of roughly 1,300 bps — a wide, demonstrably real advantage that has been sustained and in fact expanded over the past four years (FCF margin moved from 6% in FY2022 to ~29% in FY2025-2026 per the fundamentals history). This is not a thin spread at risk of immediate mean reversion. The moat has concrete mechanisms I can point to: (1) Supply-side scale economies — ResMed dominates CPAP/APAP device manufacturing with deep integration into home medical equipment provider workflows; fixed R&D and manufacturing costs are spread over a large and growing installed base. (2) Switching costs — proprietary AirView/myAir cloud platform locks in both HME providers (who manage thousands of patients through ResMed's ecosystem) and payers who rely on compliance data for reimbursement decisions; leaving means rebuilding workflows and data pipelines, a high procedural and relational cost. (3) Intangibles — regulatory 510(k) clearances and clinical validation data create meaningful barriers to entry for new device competitors, and the brand carries genuine pricing power with payers. (4) Demand-side network effects are secondary but present: the larger the patient base on AirView, the more valuable the adherence data is to payers and physicians, reinforcing the platform. Moat rating: Wide, trajectory Stable-to-Strengthening on the software/data side, with some erosion risk on hardware from GLP-1 drugs reducing OSA prevalence (a genuine outside-view threat not yet reflected in results but flagged by the market). Reading the expectations embedded in the price: At $235.50, the DCF base case implies ~$298 intrinsic value (26% upside) using 10.2% FCF growth and 8.1% WACC. The P/FCF of 20.4x and P/E of 22.1x are not demanding for a company with 33% operating margins, 21% ROIC, and ~10% revenue CAGR. What the price implies: roughly 8-10% FCF growth perpetuated for 5 years, then a 2.5% terminal growth rate — these are below the company's demonstrated 3-year revenue CAGR of ~10.2%. The embedded expectations are therefore roughly at or slightly below the recent run-rate, meaning the stock is not pricing in acceleration; it's pricing in continuation. From an expectations-investing standpoint, you don't need to be heroically optimistic — you need the moat to hold, which is the right question to ask. Distribution of outcomes: Base case (50% weight) — moat holds, GLP-1 headwind is modest (OSA is structural/anatomical for most patients, not purely weight-driven), software platform grows, FCF compounds at 8-10%, stock returns 10-15% annually. Bull case (25% weight) — GLP-1 impact is overstated, Noctrix acquisition opens wearable therapeutics adjacent market, software retention improves post-MatrixCare rationalization, intrinsic value moves toward $390. Bear case (25% weight) — GLP-1 drugs meaningfully shrink the addressable CPAP market over 5 years, ventilator recall costs exceed current $45.7M accrual (noted in the 10-K filed 2026-08-13 under Accrued Expenses: 'Field safety notification expenses $45,657'), competitive pressure from Philips recovery or new entrants compresses device margins, ROIC compresses toward 15%, fair value converges toward $233. The bear case is near current prices, providing limited margin of safety in the downside tail. Capital allocation is generally disciplined: long-term debt has dropped dramatically (from $1.435B in FY2023 per 10-K filed 2024-08-09 to $399M in FY2026 per 10-K filed 2026-08-13); FCF is being returned via dividends (raised) and repurchases; the Noctrix acquisition at $335M was bolt-on and strategically coherent. The MatrixCare divestiture, if confirmed, would improve capital focus. Concern: $21.7M in restructuring charges (nine months ended March 31, 2026, per 10-Q filed 2026-05-01) and the ventilator recall accrual bear watching. AI disruption assessment: AI is a net enhancer for ResMed in the medium term. The AirView platform already uses ML for adherence prediction and therapy optimization; AI capabilities deepen the switching cost moat by making the data ecosystem stickier. The risk is that AI commoditizes device hardware faster than ResMed can shift value to software — manageable but real. Disconfirming evidence I'd watch: (1) ROIC falling below 17% for two consecutive years signaling moat erosion; (2) GLP-1 clinical data showing >20% reduction in OSA device-eligible population; (3) ventilator recall costs materially exceeding the $45.7M accrual; (4) revenue growth decelerating below 6% on a sustained basis.

Key points

• ROIC of 21.3% vs WACC ~8.1% = ~1,300 bps spread; wide, sustained, and expanding (FCF margin from 6% in FY2022 to ~29% in FY2026 per fundamentals history)
• Moat has three concrete mechanisms: switching costs via AirView/myAir data platform locking HME providers and payers; scale economies in device manufacturing and R&D; regulatory/IP intangibles (510(k) clearances, clinical validation data)
• Expectations embedded in $235.50 price (~$298 DCF base, P/FCF 20.4x, P/E 22.1x) imply roughly continuation of historical FCF growth — not an aggressive right-tail scenario; margin of safety exists in the base case
• Balance sheet transformed: long-term debt from $1.435B (FY2023, per 10-K 2024-08-09) to $399M (FY2026, per 10-K 2026-08-13); $1.47B cash; operating cash flow $1.81B FY2026
• AI is a net moat-strengthener: ML-driven adherence analytics deepen AirView platform lock-in and increase switching costs for HME providers and payers

Red flags

• Bear case ~$233 is near current price ($235.50) — limited margin of safety in the downside tail; the distribution is not comfortably skewed to the upside
• Field safety notification accrual of $45.7M (10-K filed 2026-08-13, Accrued Expenses note) for ventilator recall is material and scope/final cost is uncertain — could exceed reserve if device population is large
• GLP-1 drug adoption reducing OSA prevalence is a structural outside-view threat to the total addressable market; base rates for medical device companies facing therapeutic substitution are not favorable
• Insider selling by CEO (~$1M, August 2026 per narrative) and $21.7M restructuring charges (10-Q filed 2026-05-01) are weak negative signals on management confidence and operational stability
• No full earnings call transcript available — cannot assess management's probabilistic framing of guidance, recall liability, or MatrixCare divestiture economics; confidence is medium not high for this reason

Valuation Referee (Damodaran-style) — 🟢 pass · 74/100 · medium confidence

ResMed's current price of $235.50 sits approximately 21% below the base-case DCF intrinsic value of $298.18 per share, implying a meaningful margin of safety on reasonable assumptions. The fact-base DCF uses a WACC of 8.11%, a 5-year explicit growth rate derived from the 3-year revenue CAGR of ~10.2%, and a terminal growth rate of 2.5% — all defensible. My independent assessment largely corroborates this, with two caveats: (1) the 10.2% FCF growth assumption is anchored to revenue CAGR, which is acceptable given RMD's demonstrated FCF margin expansion from 6% in FY2022 to ~29% in FY2025-2026 (per the fundamentals history block), but that margin expansion is now maturing and may not repeat; (2) the terminal value represents 79.2% of enterprise value, which is high but not unusual for a quality compounder with durable reinvestment economics. On the key Damodaran criteria: ROIC of 21.3% (per fundamentals) substantially exceeds the 8.1% WACC, so growth IS value-creating rather than value-destructive. The reinvestment story is internally consistent — capex of $156M against $5.65B revenue (sales-to-capital ratio well above 1x when including acquired goodwill/intangibles), supported by FCF of $1.65B. The implied market expectations at $235.50, reverse-engineered, require only ~8-9% FCF growth perpetually — below the demonstrated 3-year CAGR — meaning the price bakes in decelerating growth, not heroism. The bear-case DCF sensitivity of $233.41 (essentially at market price) is a concern: it suggests the stock has very little margin of safety if the bear assumptions materialize, particularly if ventilator recall costs, loss of the MatrixCare revenue stream post-divestiture, and/or WACC drift higher materialize simultaneously. The 10-K (filed 2026-08-13) shows field safety notification expenses for the Astral device jumped from $4.8M accrued to $45.7M accrued by June 2026 — a tenfold increase that represents a meaningful but not catastrophic liability relative to $1.65B FCF. Operating margin of 33.4% is high and already partially reflects scale efficiencies; the structural question is whether this sustains as the company reinvests (Noctrix acquisition for $335M closed June 1, 2026, per the 10-K). Debt has been largely repaid — long-term debt fell from $1.44B in FY2023 to $399M in FY2026, with net cash of ~$1.07B — materially reducing financial risk and supporting a lower cost of capital. The WACC of 8.1% with beta of 0.77 is defensible for a medical device company with this balance sheet. AI disruption risk is moderate and two-sided: AI could enhance RMD's data-connected ecosystem (AirSense/myAir platform generates vast sleep data) but also risks commoditizing device hardware and lowering reimbursement if AI-enabled alternatives emerge. Not an immediate threat over 3-5 years but worth monitoring. The MatrixCare divestiture (narrative) introduces near-term revenue mix uncertainty — fact base does not disclose proceeds or revenue impact, creating a DCF input gap. Overall: a quality business trading below a defensible intrinsic value with ROIC well above WACC and demonstrated FCF conversion, but the bear case is close to current price and several near-term uncertainties (recall liability scope, MatrixCare proceeds, FY27 guidance) are unresolved.

Key points

• DCF intrinsic value of $298.18/share vs. $235.50 current price implies ~27% upside, representing a meaningful margin of safety on base assumptions (10-K filed 2026-08-13, fundamentals block)
• ROIC of 21.3% vs. WACC of 8.1% confirms growth is materially value-creating; a spread of ~13 percentage points is a high-quality signal (fundamentals block)
• FCF margin expanded from 6.1% in FY2022 to 29.2% in FY2026 demonstrating genuine operating leverage, though the easy margin expansion phase appears mature (fundamentals history)
• Debt dramatically reduced: long-term debt fell from $1.44B (FY2023) to $399M (FY2026) while cash is $1.47B, yielding net cash of ~$1.07B — meaningfully reduces WACC and financial risk (10-K 2026-08-13)
• Reverse-engineered implied growth at $235.50 is approximately 8-9% — well below demonstrated 3-year CAGR of 10.2%, meaning market expectations appear beatable on historical evidence
• Terminal value at 79.2% of EV is elevated but defensible given demonstrated durable FCF; terminal growth of 2.5% is at/below nominal GDP — not heroic
• Astral field safety notification accrual rose from $4.8M to $45.7M (10-K 2026-08-13) — quantifiable headwind but contained relative to $1.65B FCF

Red flags

• Bear-case DCF sensitivity of $233.41 is nearly at current price ($235.50), meaning very limited margin of safety if growth decelerates or WACC rises even modestly — the investment requires at least base-case execution
• Terminal value represents 79.2% of total enterprise value — any error in the terminal growth or terminal margin assumptions has an outsized impact on intrinsic value
• MatrixCare divestiture announced (narrative) but proceeds, revenue impact, and segment contribution not disclosed in available fact base — creates a meaningful gap in revenue/FCF projection inputs
• Ventilator recall (Astral) scope beyond the $45.7M accrual is uncertain; narrative cites UBS flagging this as clouding FY27 visibility, but no regulatory filing details or full cost range available
• FCF growth assumption anchored to revenue CAGR may overstate future FCF growth if the exceptional margin expansion (6% to 29% over 4 years) does not continue — base FCF of $1.65B to grow at 10.2% requires sustained margin stability
• $335M Noctrix acquisition (10-K 2026-08-13) is preliminary purchase price allocation — ROIC dilution from this deal is unknown pending final intangible fair value assessment
• No earnings call transcript available (narrative caveat) — cannot assess management guidance, tone, or forward margin trajectory, reducing confidence in projections

Ray Dalio — 🟢 pass · 72/100 · medium confidence

ResMed is a medical device compounder with genuinely non-discretionary demand (CPAP/BiPAP therapy for OSA is clinically mandated, insurer-reimbursed, and not easily deferred), a nearly debt-free balance sheet, and record free cash flow generation. From a Dalio macro-stress frame, this is not a classic macro-sensitive name, but it is far from immune — I must stress-test it across regimes, assess its debt-cycle exposure, and rate sensitivity before issuing a verdict.

Regime robustness: OSA prevalence and treatment initiation are driven by demographics and clinical protocols, not the business cycle. In a deflationary bust, reimbursement rates could be cut by payers (government and private insurers) — this is the primary bear case in a deleveraging scenario. In stagflation, higher input costs (chips, plastics, freight) compress margins, but ResMed demonstrated strong pass-through pricing power as FCF margins expanded from 6% in FY2022 to ~29% in FY2026 (fundamentals history). In a rising-growth/rising-inflation boom, the business is straightforward beneficiary. The weakest box for RMD is deflationary deleveraging with healthcare austerity — Medicare/Medicaid cuts are a genuine tail. Overall, the business holds up reasonably across 3 of 4 regimes, with one meaningful vulnerability.

Balance-sheet resilience: The 10-K filed 2026-08-13 shows long-term debt of $399M against cash of $1.47B — a net cash position of approximately $1.07B (confirmed by the valuation block: net_debt = -$1.07B). Debt-to-equity is 0.06 (fundamentals). Total liabilities of $2.38B against stockholders' equity of $6.59B. Short-term debt jumped to $260M at June 30, 2026 from $10M a year prior (10-K filing note 8) — this warrants watching as a near-term maturity, but the cash hoard dwarfs it. Interest coverage is extremely high given ~$50M of net interest INCOME in FY2026 (10-K segment reconciliation: interest income/expense net = +$49.9M). This balance sheet easily survives a multi-year credit crunch without accessing capital markets — a core Dalio requirement.

Rate environment sensitivity: With net cash and positive interest income, rising rates are actually a modest tailwind to the income statement, not a headwind. Demand for CPAP therapy is not rate-sensitive (patients do not finance CPAP purchases at a rate-sensitive margin; reimbursement is insurer/government-driven). No meaningful floating-rate debt exposure visible in filings. Rate sensitivity is LOW — a clear positive.

Inflation pass-through: FCF margin expansion from 6% (FY2022) to 29% (FY2025-26) through the highest inflation cycle in 40 years demonstrates strong pricing power and/or input cost management. Operating margin of 33.4% in FY2026 (fundamentals). This is credible real-return protection.

Debt-cycle position: ResMed's customers (patients/insurers/hospitals) are not leveraged buyers; OSA therapy is a recurring consumable/device need funded primarily by insurance reimbursement rather than patient credit. This insulates demand from private-sector deleveraging. The $335M Noctrix acquisition (completed June 1, 2026, per 10-K) was funded from operating cash, not new debt. No signs of credit-cycle dependence.

Geographic/FX diversification: The company operates globally with international revenues (segment data not fully broken out in available excerpts, but operating lease revenue alone covers multiple foreign geographies per 10-K). FX hedging instruments visible in accrued expenses ($16.6M at June 30, 2026 vs. $2.7M prior year — 10-K note 7), indicating active FX management. Geographic diversification is real but concentration detail is missing from the available filing excerpts.

Key risks from a Dalio frame: (1) Healthcare policy/reimbursement cuts in a fiscal austerity scenario — this is the dominant macro tail risk. (2) The ventilator recall (flagged by UBS per narrative; field safety notification accruals jumped to $45.7M at June 30, 2026 from $4.8M a year earlier per 10-K note 7) represents an operational/regulatory tail that could become a balance-sheet burden if scope expands. (3) MatrixCare divestiture signals portfolio simplification; proceeds and strategic pivot are unclear from available material. (4) The DCF assigns 79.2% of value to terminal value — this is a long-duration equity with meaningful sensitivity to terminal growth assumptions, which is a Dalio-style concern in a structurally higher-rate regime (WACC of 8.11% may be too low if rates stay elevated). (5) PEG of 2.16 and P/S of 5.94 are not stretched for the quality, but the DCF bear case of $233/share is essentially current price — limited downside cushion.

AI disruption assessment: AI is a moderate net positive for ResMed on a 3-10 year horizon. The company's AirSense connected device platform generates sleep health data at scale; AI-driven adherence monitoring and remote patient management (which ResMed already does through myAir) are competitive moats, not threats. The primary AI risk is commoditization of diagnostic algorithms if smartphone-based OSA screening proliferates and reduces need for PSG titration and device prescription — but this would expand the addressable market rather than disintermediate existing therapy. Not a material negative from this lens.

Scoring rationale: Regime robustness (~3/4 boxes), pristine balance sheet, rate-positive net cash, demonstrated inflation pass-through, and non-discretionary demand are strong Dalio positives. The deductions: single largest risk (reimbursement policy) is a genuine macro tail; long-duration DCF valuation is vulnerable to a persistently high WACC; the field safety notification liability spike is unresolved; and the short-term debt maturity increase bears monitoring. Score: 72 — a narrow pass.

Key points

• Net cash position of ~$1.07B (10-K FY2026: $1.47B cash vs. $399M long-term debt + $260M short-term debt); balance sheet is self-funding through any foreseeable downturn without capital market access
• Interest income turned net positive at +$49.9M in FY2026 (10-K segment reconciliation), meaning rising rates are a mild tailwind, not a headwind — eliminates a major Dalio red flag
• FCF margin expanded from 6% (FY2022) to 29% (FY2025-26) through the inflation cycle, demonstrating real pricing power and inflation pass-through
• Demand is insurer/government-reimbursed for a clinically mandated therapy — not credit-cycle dependent; patients do not finance CPAP via rate-sensitive debt
• Regime robustness is above-average for a healthcare device name: OSA therapy holds across boom, stagflation, and disinflationary growth; primary vulnerability is fiscal austerity/reimbursement cuts in a deleveraging scenario
• Geographic revenue diversification with active FX hedging ($16.6M hedging instruments at June 30, 2026 per 10-K note 7); AI-enhanced connected device platform (myAir) is a moat, not a disruption risk

Red flags

• Field safety notification accrual jumped to $45.7M at June 30, 2026 from $4.8M a year prior (10-K note 7) — ventilator recall scope and ultimate liability are unresolved; this is an unquantified balance-sheet tail
• Short-term debt increased to $260M at June 30, 2026 from $10M a year prior (10-K note 8) — near-term maturity that warrants monitoring, though fully covered by $1.47B cash
• 79.2% of DCF value resides in terminal value; in a structurally higher WACC environment (8.11% base may be optimistic), intrinsic value is highly sensitive to rate-regime assumption — bear case $233/share is essentially current price
• Healthcare reimbursement policy risk (Medicare/Medicaid austerity) is the dominant macro tail — a fiscal consolidation cycle could compress revenue and margins without any operational failure by management
• MatrixCare divestiture rationale, proceeds, and buyer terms not available in material — introduces strategic execution uncertainty that is difficult to stress-test

AI & Disruption Referee (Christensen-style) — 🟢 pass · 72/100 · medium confidence

ResMed's core business — manufacturing and distributing CPAP/BiPAP devices and masks for obstructive sleep apnea and respiratory care — is fundamentally a hardware + regulated medical device franchise, not a knowledge-work intermediary or software toll-taker. The job it does for customers is physical: deliver calibrated positive airway pressure therapy through FDA-cleared, physician-prescribed hardware. AI cannot replicate this at the point of care — a language model cannot treat OSA. The disintermediation risk profile is therefore structurally low on the device side. However, ResMed also operates a digital health ecosystem (AirSense connected devices, myAir patient app, AirView provider platform) and a Residential Care Software segment (recently divesting MatrixCare per the narrative). The software/data layer is where AI disruption risk is real and must be assessed separately. On the device side, AI is more plausibly a tailwind: ResMed's connected device fleet generates proprietary sleep and respiratory data at scale from tens of millions of patients nightly — a feedback loop that gets more valuable as AI improves pattern recognition for therapy optimization, adherence prediction, and early disease detection. This proprietary longitudinal dataset is genuinely hard to replicate without the installed base, which compounds rather than erodes over time. The moat is clinical data network effects plus regulatory clearance plus physician/payer workflow lock-in — none of which a foundation model plus first-party customer data can easily replicate. The Residential Care Software segment (home health scheduling, EHR, etc.) carried higher disruption risk as an intermediary workflow software layer potentially commoditizable by AI-native entrants or hyperscaler bundles — but the narrative reports the MatrixCare divestiture, suggesting management may be strategically shedding the most exposed segment, which is a point in their favor. Key uncertainties: (1) the ventilator recall overhang (noted by UBS per narrative) is a near-term headwind unrelated to AI; (2) management's AI strategy is not detailed in available filings or transcripts — no earnings call transcript is present in the fact base, so cannot assess whether they are investing meaningfully in proprietary AI on their data layer or treating it as a feature add; (3) hyperscalers like Apple (HealthKit) or Google (health AI) could potentially compete in sleep monitoring via wearables, commoditizing the diagnostic/monitoring function though not the therapeutic device itself. The bear case on AI is specifically: if wearable AI (Apple Watch, Oura Ring) becomes accurate enough for OSA diagnosis and remote titration platforms emerge, ResMed's device moat could face substitution pressure at the margin over 7-10 years, but not within the typical investment horizon for a core therapy device. Score 72: not a high-conviction pass because the software segment disruption risk is real (partially mitigated by divestiture), management AI transparency is unverifiable from available data, and wearable monitoring is a genuine 7-10 year threat to watch. But the core hardware+data franchise is structurally resilient to AI commoditization in the 3-10 year window.

Key points

• Core CPAP/BiPAP device business is physically delivered regulated therapy — AI cannot disintermediate the therapeutic hardware itself; the job-to-be-done requires FDA-cleared hardware titrated to patient physiology
• Proprietary connected device data from tens of millions of patients nightly (AirSense platform, AirView, myAir) is a compounding data moat: more patients → better AI models for adherence and therapy optimization → stronger clinical outcomes → more prescriptions — classic flywheel that AI amplifies rather than destroys
• MatrixCare divestiture (per narrative, July 2026) strategically sheds the highest-disruption-risk segment — workflow scheduling/EHR software for home health is exactly where AI-native competitors and hyperscaler bundles would have attacked; exiting this exposure is AI-aware capital allocation
• Regulatory moat is durable: FDA 510(k)/PMA clearance, physician prescription requirements, payer reimbursement coding (HCPCS) all create switching friction that no AI model can shortcut — the regulatory layer is structural protection against AI-native entrants
• Revenue CAGR of ~10% (per fundamentals block) and FCF margin expansion from 6% (FY2022) to 29% (FY2026) suggest the data/connected health strategy is already driving operating leverage, consistent with AI tailwind rather than threat
• Beta of 0.77 (fundamentals) reflects low correlation with tech sentiment — market is not pricing in AI disruption risk in the way it would for a software intermediary

Red flags

• No earnings call transcript available — cannot verify whether management has a concrete, funded AI/data strategy or is treating it as marketing veneer; this is a material evidence gap for this lens
• Wearable OSA monitoring (Apple Watch, Oura Ring, consumer sleep tech) represents a 7-10 year substitution risk at the diagnostic and mild-OSA monitoring end of the market — if diagnosis migrates to consumer wearables, referral volumes to ResMed devices could face structural headwinds at the margin
• Residential Care Software segment (pre-divestiture) carried genuine AI commoditization exposure as a workflow intermediary; the field safety notification expense accrual of $45.7M (10-K filed 2026-08-13, Accrued Expenses table) and the $21.7M restructuring charge (10-Q filed 2026-05-01) suggest the software segment was already under operational stress before AI risk fully materializes
• Hyperscaler health platform risk: Google Health, Apple Health, and Amazon Clinic have data and distribution advantages in consumer health that could commoditize the monitoring/coaching layer of ResMed's digital ecosystem (myAir, AirView) even if the therapy device itself is protected
• The 'falsifiable confirm' signal to watch: if myAir/AirView take-rates or SaaS pricing compress, if payers begin reimbursing AI-powered remote monitoring platforms as substitutes for CPAP titration, or if Apple/Google announce OSA diagnostic clearances — any of these would confirm commoditization pressure on the digital layer

Forensic Short-Seller (Chanos/Einhorn-style) — 🟢 pass · 72/100 · medium confidence

Running the Chanos/Einhorn forensic checklist on ResMed produces a largely clean result, with a few items worth monitoring but no smoking-gun red flags. The core short-seller test — net income vs. operating cash flow — actually vindicates the earnings quality here. Over the reported history in the fact base, operating cash flow ($1,806M for FY2026, per fundamentals) tracks closely to or exceeds net income ($1,523M), and FCF ($1,650M) is robust and near net income. This is the opposite of the accrual-inflation pattern Chanos targets. The FCF margin has expanded dramatically from 6% in FY2022 to ~29% in FY2025-2026 (per the historical table in fundamentals), which is characteristic of a business where earnings quality is improving, not deteriorating. The heavy debt load visible in FY2023 ($1.44B long-term debt per the 10-K filed 2024-08-09) has been meaningfully reduced to $399M long-term debt by June 30, 2026 (per 10-K filed 2026-08-13), with $1.47B cash on hand, a net cash position, eliminating the debt-wall concern. Working capital is healthy at 3.1x current ratio. Shares outstanding show modest decline (147M diluted in FY2024 to ~146M in FY2025, per 10-K disclosures), suggesting buybacks are at least partially offsetting SBC rather than pure dilution treadmill — though the shrinkage is modest. Non-GAAP adjustments are real but disclosed and relatively contained: the 10-K filed 2026-08-13 shows GAAP operating income of ~$1,887M versus non-GAAP adding back amortization of acquired intangibles and field safety notification charges; these are disclosed with full reconciliation and the GAAP earnings are not trivially negative. The field safety notification expense spike ($45.7M accrued at June 30, 2026 vs. $4.8M prior year, per 10-K 2026-08-13) is a genuine one-time-ish item worth tracking — it jumped ~10x in the accrual, tied to masks-with-magnets and Astral device replacement programs. The Noctrix acquisition for $335M (June 1, 2026 per 10-K 2026-08-13) is modest relative to cash position and is preliminary in purchase price allocation, a normal risk but not alarming. The narrative flags ventilator recall uncertainty (UBS commentary in narrative digest) and the MatrixCare divestiture, both of which are real but disclosed operational items rather than accounting manipulation. CEO insider selling of ~$1M in August 2026 (per narrative) is immaterial. The principal genuine forensic concern is the $260M of short-term debt appearing at June 30, 2026 (vs. $10M prior year, per 10-K 2026-08-13), which is a notable shift that bears watching for refinancing — though with $1.47B cash this is not a survival risk. Unbilled receivables are modest ($47M per 10-Q filed 2026-05-01). In sum, this is a well-managed, cash-generative medical device business with clean earnings quality — not a Chanos-style target. The score reflects 'pass' from a forensic standpoint, meaning the short case is weak, though the ventilator recall liability and field safety notification reserve build warrant ongoing scrutiny.

Key points

• Operating cash flow ($1,806M) exceeds net income ($1,523M) for FY2026 (fundamentals block) — earnings quality is high, the core short-seller test fails to fire
• FCF margin expanded from 6% in FY2022 to ~29% in FY2025-2026 (historical table in fundamentals), demonstrating genuine cash conversion improvement, not deterioration
• Long-term debt reduced from $1.44B (June 30, 2023, per 10-K filed 2024-08-09) to $399M (June 30, 2026, per 10-K filed 2026-08-13) with $1.47B cash — net cash position eliminates debt-wall thesis
• Non-GAAP adjustments are disclosed with full reconciliation; GAAP operating margin of 33.4% (fundamentals) is itself strong, limiting concern about non-GAAP reliance
• Diluted shares ~146M in FY2026 vs. ~148M in FY2024 (per 10-K filings) — modest but genuine shrinkage, not a pure dilution treadmill
• Current ratio of 3.1x and $1.47B cash provide strong liquidity buffer (10-K filed 2026-08-13)

Red flags

• Field safety notification expense accrual jumped from $4.8M to $45.7M at June 30, 2026 (10-K filed 2026-08-13) — a ~10x spike for masks-with-magnets and Astral device programs; scope and ultimate liability not fully bounded in available filings
• Short-term debt rose abruptly from $10M (June 30, 2025) to $260M (June 30, 2026) per 10-K filed 2026-08-13 — needs monitoring for refinancing pressure even though cash covers it
• Noctrix acquisition ($335M, June 2026, per 10-K filed 2026-08-13) has preliminary purchase price allocation; integration risk and intangible write-down risk not yet fully visible
• Ventilator recall scope and FY27 financial impact not quantified in available filings — UBS commentary in narrative flags this as an overhang but no reserve estimate is visible in the fact base
• $21.7M restructuring charge in nine months ended March 31, 2026 (10-Q filed 2026-05-01) for workforce reduction is a sign of ongoing cost structure adjustment; watch for recurring 'one-time' characterization
• Insider CEO stock sale (~$1M, August 2026 per narrative) is small but noted; no broader cluster selling pattern visible in available data — insufficient Form 4 detail in fact base to draw firm conclusions

Joel Greenblatt — 🟡 watch · 62/100 · medium confidence

ResMed is a high-quality operating business with strong and measurable ROIC characteristics, but the current price leaves the earnings yield only modestly attractive on a Magic Formula basis — good business, fair-to-slightly-cheap price rather than a screaming bargain. Working through the two Greenblatt inputs: (1) ROIC (EBIT / net working capital + net fixed assets): EBIT for FY2026 was $1,887M (10-K filed 2026-08-13). Net working capital = current assets $4,325M minus current liabilities $1,395M = $2,930M. Net fixed assets (PP&E net) from the 10-Q filings show roughly ~$567M as of March 2026. So tangible capital employed ≈ $2,930M + $567M = $3,497M. EBIT/tangible capital ≈ $1,887M / $3,497M ≈ 54%. That is an excellent ROIC by any standard — this is clearly a high-quality, capital-light operating franchise. The caveat is that current assets are inflated by $1.47B of cash; stripping excess cash (say, keep $200M as operating float, treat $1.27B as excess) reduces net working capital to ~$1.66B, giving tangible capital of ~$2.23B and ROIC of ~85% — extraordinary. Either way, the business earns very high returns on tangible capital. (2) Earnings yield (EBIT/EV): Market cap ~$33.6B. Total debt from 10-K: short-term $260M + long-term $399M = $659M gross debt. Cash $1,469M. Net debt = -$810M (net cash position). EV = $33,608M + $659M - $1,469M ≈ $32,798M. Earnings yield = $1,887M / $32,798M ≈ 5.75%. On absolute terms, 5.75% is acceptable but not cheap for Greenblatt's framework — the Magic Formula thrives when earnings yields are 10%+ on genuinely good businesses. At ~5.75%, RMD is priced as a quality compounder at a modest discount (the DCF suggests ~27% upside to $298 intrinsic value), but it is not the statistically cheap end of the formula screen. The combination — excellent ROIC (~54-85%) but only modest earnings yield (~5.75%) — puts this squarely in 'good business at a fair-to-slightly-cheap price' territory rather than the Magic Formula sweet spot. Special situation angle: the MatrixCare divestiture (announced July 2026 per the narrative) is a potential catalyst. Spinoffs and divestitures often unlock value as capital is redeployed and the core sleep/breathing business is more clearly valued. However, the fact base is thin on this — no proceeds disclosed, no buyer named, no timeline confirmed. The Noctrix acquisition ($335M, closed June 2026, per 10-K) is digestible given FCF of $1.65B. FCF conversion is excellent: FCF $1,650M vs EBIT $1,887M = ~87% conversion, confirming earnings quality. Operating cash flow $1,806M vs net income $1,523M confirms no significant accrual inflation. AI disruption assessment: ResMed's moat is in proprietary CPAP/BiPAP device hardware, a large installed patient base with high switching costs, data analytics from 15+ years of connected-device sleep data (AirSense platform), and deep integration with healthcare reimbursement pathways. AI could enhance ReMed's diagnostic and remote monitoring capabilities — this is a durably strengthening factor. The primary AI risk is if GLP-1 drugs (Ozempic, Wegovy) materially reduce the OSA patient population over time by treating obesity — but this is a medium-term demand risk, not an AI disruption per se, and remains speculative. From a pure Greenblatt lens, this is a high-ROIC business not yet cheap enough to be a top decile Magic Formula pick. The MatrixCare divestiture catalyst is real but underspecified. Ventilator recall liability (flagged by UBS per narrative) adds earnings uncertainty. Score: 62 — watch, not pass.

Key points

• ROIC on tangible capital (EBIT / NWC + net PP&E) is approximately 54-85% depending on excess cash treatment — clearly a high-quality business by Greenblatt standards
• Earnings yield (EBIT/EV) is approximately 5.75% ($1,887M EBIT / ~$32.8B EV) — acceptable but not cheap enough for a top Magic Formula rank
• FCF conversion of ~87% (FCF $1,650M vs EBIT $1,887M) confirms real, repeatable operating earnings with minimal accrual inflation (per 10-K filed 2026-08-13)
• MatrixCare divestiture announced July 2026 is a potential special-situation catalyst that could sharpen the core sleep/breathing business focus and unlock value, but proceeds and timeline are unspecified in the fact base
• Net cash position (~$810M net cash) means EV is modestly below market cap, slightly enhancing earnings yield; balance sheet is clean with debt/equity of only 6% (per fundamentals)
• Revenue CAGR of ~10% over 3 years with operating margin of 33% confirms the pricing power and operating leverage of the franchise

Red flags

• Earnings yield of ~5.75% is not in the bargain zone for a Magic Formula screen — RMD is priced for quality, limiting upside on the cheapness axis
• Ventilator recall liability (UBS flagged, per narrative) introduces earnings uncertainty; field safety notification expenses in accrued liabilities jumped from $4.8M to $45.7M year-over-year (10-K filed 2026-08-13) — a significant contingent cost increase
• Restructuring charges of $21.7M in nine months ended March 2026 (10-Q filed 2026-05-01) add noise to normalized EBIT — requires adjustment for true earnings power
• MatrixCare divestiture lacks disclosed financials in fact base — cannot assess capital reallocation quality or whether proceeds will be returned to shareholders vs. redeployed into lower-ROIC acquisitions
• Noctrix acquisition at $335M (10-K 2026-08-13) is early-stage wearable therapeutics; purchase price allocation still preliminary, adding uncertainty to goodwill and intangible asset quality
• No earnings call transcript available — cannot assess management candor on recall scope, FY27 guidance, or capital allocation post-MatrixCare sale

Bruce Greenwald — 🟡 watch · 62/100 · medium confidence

ResMed is a legitimate franchise business that passes the basic EPV/moat test — EPV meaningfully exceeds reproduction value — but the current market price demands paying for growth, and several items cloud the normalized earnings picture. Let me work through the analysis rigorously.

EPV Calculation (normalized earnings, no growth assumed): FY2026 GAAP operating income from fundamentals: $1,886,715,000 (10-K filed 2026-08-13, 33.4% operating margin). Adjusting for non-recurring items visible in filings: field safety notification expenses for masks-with-magnets and Astral devices appear in accrued expenses ($45.7M for field safety in FY2026 vs $4.8M in FY2025 per the 10-K excerpt), acquisition/portfolio review expenses of $11.5M (10-K, FY2026), plus amortization of acquired intangibles embedded in operating expenses. The 10-K non-GAAP reconciliation shows amortization of acquired intangibles running ~$79M/year (D&A by segment table shows total D&A $201M, with $78.3M being acquired intangibles/corporate amortization). Restructuring in FY2026 was modest (~$21.7M per Q3 10-Q). Normalizing: add back field safety (~$45M above-trend; FY2025 base was ~$5M), add back acquisition expenses ($11.5M), add back restructuring ($21.7M), subtract excess amortization vs. maintenance capex. Capex was $156M (fundamentals) vs depreciation of ~$103M on PP&E (10-K), suggesting modest growth capex component. Using adjusted operating income of roughly $1,950-2,000M pre-tax normalized, tax-affected at ~20.6% effective rate (net income $1,523M / pre-tax income $1,919M per 10-K segment table), gives NOPAT of ~$1,550-1,590M. Capitalizing at WACC of 8.11% (from valuation block): EPV ≈ $19.1-19.6B enterprise value. Adding net cash of ~$1.07B (valuation block net debt figure): EPV equity ≈ $20.2-20.7B, or approximately $140-143/share on 144.25M shares. Current price is $235.50 — roughly 65% above EPV. This is the core Greenwald concern: the market price demands substantial growth above the no-growth EPV.

Reproduction Value / Moat Assessment: ResMed's asset base is tangible PP&E net ~$567M (Q3 10-Q), goodwill and intangibles that are substantial (customer relationships $484M gross, developed technology $396M gross per Q3 10-Q — though these are accounting values of acquired assets, not reproduction costs). Reproducing ResMed's actual competitive position would require: (1) building clinical trial data and regulatory approval for CPAP/APAP devices across 140+ countries — likely $1-2B in time and capital; (2) rebuilding the AirView remote monitoring platform with its 10M+ patient data advantage — arguably the most durable moat element, not reflected on the balance sheet; (3) rebuilding physician and DME distributor relationships; (4) rebuilding the mask accessory consumable franchise which generates recurring revenue. My rough estimate of tangible + real reproduction cost of intangibles is $6-9B, substantially below EPV of ~$20B. This EPV >> reproduction value gap confirms a genuine franchise — ResMed earns above cost of capital not by accident but through real barriers: customer captivity (patients habituated to specific mask interfaces, physicians embedded in AirView ecosystem), economies of scale in a niche (sleep apnea is large but specialized), and proprietary connected-device platform data network effects. The moat is real.

What the Gap Between Price and EPV Implies: At $235.50, the market is paying approximately $13-14B above EPV. Using WACC 8.11% and terminal growth 2.5%, that gap implies the market expects roughly $1.1-1.3B of additional annual normalized earnings from growth — or approximately 70-80% growth in earnings power from current levels. The 3-year revenue CAGR is 10.2% (fundamentals), and FCF has grown dramatically (from $216M in FY2022 to $1.65B in FY2026 — though FY2022 was depressed by supply constraints post-Philips recall; normalization is tricky). The DCF provided (intrinsic $298/share) uses 10.2% FCF growth for 5 years — this is the growth-assumption-laden approach Greenwald explicitly distrusts. The terminal value represents 79.2% of enterprise value (valuation block), which is exactly the long-horizon terminal value dependence that hides errors.

Earnings Quality Concerns: FCF margin jumped from 6% (FY2022) to 13.6% (FY2023) to 27.8% (FY2024) to 32.3% (FY2025) to 29.2% (FY2026). The dramatic improvement partly reflects Philips recall beneficiary tailwinds (Philips' CPAP recall pulled market share to ResMed), normalization of supply chain inventory, and debt paydown. These are real but potentially one-cycle improvements rather than permanently sustainable margin levels. Field safety notification accruals ($45.7M vs $4.8M prior year) and ventilator recall risk (cited in narrative as clouding FY27) add uncertainty to normalized earnings. MatrixCare divestiture (mentioned in narrative) may alter segment mix. No earnings call transcript is available to assess management's own characterization of sustainable margins.

AI/Disruption Assessment: AI is a mixed factor here. ResMed's AirView platform generates continuous patient monitoring data; AI-enhanced diagnostics could deepen physician dependence on the platform (moat-enhancing). However, AI-enabled at-home sleep testing and diagnosis (replacing overnight polysomnography) could expand the addressable market. On the risk side, AI could commoditize device algorithms over time, and new entrants with superior connected-platform AI could theoretically disrupt. Net assessment: AI is more likely moat-enhancing than disruptive over a 3-10 year horizon given ResMed's data advantage, but this is speculative and not a reason to pay up today.

Balance Sheet: Excellent. Net cash positive (~$1.07B net cash per valuation block), current ratio 3.1x (fundamentals), debt-to-equity 0.06x. Long-term debt $399M (10-K FY2026). The Noctrix acquisition ($335M, June 2026, per 10-K) was small relative to cash generation. Financial risk is minimal.

Summary: ResMed passes the moat test convincingly — EPV substantially exceeds reproduction value, confirming a genuine franchise. However, at $235.50, the price is ~65% above my EPV estimate of ~$140-143/share. A Greenwald margin of safety requires buying at or below EPV, not 65% above it. The price only works if one trusts 10%+ growth for many years inside the moat — which may well happen, but that is growth-dependent valuation, exactly what the EPV framework rejects as a primary anchor. The stock is a 'watch' rather than 'avoid' because the moat is real, the balance sheet is clean, and the franchise is durable — but the entry price demands paying heavily for speculative growth.

Key points

• EPV estimate ~$140-143/share (normalized NOPAT ~$1,550-1,590M capitalized at 8.11% WACC), well below current price of $235.50 — market embeds substantial growth premium
• EPV >> reproduction value confirms genuine franchise: AirView data platform, customer captivity in mask accessories, regulatory barriers, and DME distribution relationships create real barriers to entry
• FCF margin expansion from 6% (FY2022) to 29-32% (FY2025-26) partly reflects one-cycle Philips recall beneficiary tailwinds; normalized earnings power requires cycle-adjustment
• Balance sheet is fortress-quality: net cash ~$1.07B, long-term debt only $399M (10-K FY2026), current ratio 3.1x — no financial distress risk
• Provided DCF ($298 intrinsic) relies on terminal value = 79.2% of enterprise value and 10.2% FCF growth — exactly the long-horizon growth assumptions Greenwald framework explicitly discounts
• AI likely moat-enhancing via AirView data platform deepening physician lock-in, not a near-term disruption threat
• Institutional accumulation (State Street, Deutsche Bank, CalSTRS per narrative) provides some comfort but does not change the EPV arithmetic

Red flags

• Price ~65% above EPV: requires sustained high growth inside the moat to justify — violates Greenwald's first principle of buying at/below EPV
• Field safety notification accruals jumped from $4.8M to $45.7M (FY2025 to FY2026 per 10-K) — ventilator recall mentioned by UBS as clouding FY27; normalized earnings harder to anchor
• No earnings call transcript available — cannot assess management guidance, margin sustainability claims, or ventilator recall scope and remediation costs
• FCF normalization ambiguous: dramatic ramp from FY2022 base (distorted by supply constraints and Philips recall share gains) makes sustainable earnings power hard to isolate
• MatrixCare divestiture (narrative, July 2026) changes segment mix; no proceeds, timeline, or earnings impact disclosed in available material
• Terminal value = 79.2% of provided DCF — the growth-dependent valuation framework most likely to hide errors per Greenwald methodology
• Restructuring charges ($21.7M in first 9 months FY2026 per Q3 10-Q) add further noise to normalized operating earnings

Howard Marks — 🟡 watch · 58/100 · medium confidence

ResMed presents a genuinely interesting tension: a high-quality franchise trading roughly 15% below its 52-week high, with real FCF generation ($1.65B, 29% margin per the 10-K filed 2026-08-13) and a balance sheet that is nearly unleveraged (long-term debt of $399M vs. $1.47B cash, yielding net cash of ~$1.07B per the valuation block). The DCF intrinsic value of $298/share vs. a $235.50 price implies a 26.6% upside — not a deep-discount, but a meaningful gap if the assumptions hold. The margin of safety question, however, is where the Marks framework gets uncomfortable. The DCF terminal value accounts for 79.2% of enterprise value — a structural dependence on a long, smooth growth runway that is the precise kind of optimism I distrust when it's baked into the math. The base FCF growth assumption of ~10.2% (equal to 3-year revenue CAGR) applied to a $1.65B base for five years, then capitalized at a 2.5% terminal rate, requires nearly everything to go right for a sustained decade-plus. That is not a conservative estimate; it is a consensus-friendly one. On the positive side, the sentiment picture has some contrarian texture: the stock is down ~9% over 52 weeks, there is active institutional accumulation (State Street, Deutsche Bank, CalSTRS per the narrative), an RBC upgrade post-downgrade in September 2026, and real headline overhang from the ventilator recall and MatrixCare divestiture — the kind of fear-inducing noise that can create price dislocations. The balance sheet is genuinely strong: D/E of 0.06 (fundamentals block), current ratio of 3.1, ROIC of 21.3%, and FCF conversion that went from 6% in FY2022 to 29% in FY2026 (fundamentals history) — this is not a fragile structure. However, the price is not 'distressed' or 'panicked' in any meaningful sense. At 22x GAAP earnings, 20x FCF, and 5.9x sales (fundamentals block), these are quality-growth multiples that already embed a durable competitive position. The bar to clear is not low — the consensus bull thesis (OSA market expansion, FCF re-rating) is broadly well-understood. Second-level thinking requires asking: what does the market have wrong? The ventilator recall cloud (noted by UBS, per narrative) and the MatrixCare divestiture uncertainty are real near-term overhangs, but the scope of remediation costs is unknown — field safety notification expenses jumped from $4.8M to $45.7M accrued at June 30, 2026 (10-K, Note 7) for masks and Astral devices, which is material but not catastrophic relative to $1.65B FCF. The restructuring of $21.7M in nine months ended March 2026 (10-Q filed 2026-05-01) and the Noctrix acquisition at $335M (10-K, Note 18) suggest capital allocation is active but not reckless. AI risk is real but not existential in the near term — AI could improve CPAP adherence analytics and remote monitoring (potentially strengthening ResMed's data moat), but could also commoditize device intelligence and reduce switching costs over a 5-10 year horizon. The Residential Care Software segment's repeated lease impairments ($2.7M in Q2 and Q3 FY2026 per the 10-Qs, $4.1M in FY2024 per the prior 10-K) suggest softness in that unit, partially resolved by the MatrixCare sale. Overall: this is a 'watch' — not cheap enough by Marks standards to be a screaming buy (no real capitulation, no distressed pricing, no balance-sheet asymmetry that tilts the risk/return dramatically), but the combination of modest discount to DCF value, strong balance sheet, and genuine but manageable headline risks keeps it out of 'avoid' territory. The loser's game risk is the 79% terminal-value dependency and quality-multiple pricing that leaves little room for error.

Key points

• Balance sheet is fortress-like: net cash position of ~$1.07B (long-term debt $399M vs. cash $1.47B per 10-K 2026-08-13 and valuation block), D/E of 0.06, current ratio of 3.1 — survivability in a downturn is high
• FCF conversion has dramatically improved: from 6% margin in FY2022 to 29% in FY2026 (fundamentals history), generating $1.65B in FY2026 — real cash, not accounting fiction
• Sentiment has some contrarian texture: stock -9% over 52 weeks, ventilator recall and MatrixCare divestiture create headline fear, yet institutional buyers (State Street, Deutsche Bank, CalSTRS) are accumulating per the narrative
• DCF shows 26.6% upside to $298 intrinsic value vs. $235.50 price — a real but not exceptional margin of safety by distressed-investor standards
• Field safety notification accrual for Astral devices jumped from $4.8M to $45.7M at June 30, 2026 (10-K Note 7) — material but contained relative to FCF scale; scope is the key unknown
• ROIC of 21.3% and operating margin of 33.4% (fundamentals block) confirm durable economics, but these are already reflected in the 20-22x earnings multiple

Red flags

• Terminal value represents 79.2% of enterprise value in the DCF (valuation block) — a classic sign that the intrinsic value calculation depends on an optimistic long-duration growth story rather than near-term demonstrated cash flows; this is the kind of assumption I distrust
• Quality-growth multiples (22x GAAP P/E, 20x FCF, 5.9x sales) reflect a fully-known, broadly-loved thesis — the OSA growth story is consensus, not a neglected variant view; the bar to meet embedded expectations is not low
• Ventilator recall scope is unknown: UBS flagged it clouds FY27 guidance (narrative) but no quantification of liability or remediation cost appears in the available filings beyond the Astral accrual — this is an unpriced tail risk
• No earnings call transcript available (narrative caveat) — cannot verify management candor on recall timeline, MatrixCare divestiture proceeds, or FY27 guidance; confidence in the forward cash flow picture is reduced
• Restructuring charges of $21.7M in nine months ended March 2026 (10-Q filed 2026-05-01), and prior FY2024 restructuring of $64.2M (10-K 2025-08-08), suggest the business footprint is still being optimized — not a red flag alone, but adds execution uncertainty
• CEO insider selling ~$1M in August 2026 (narrative) is not alarming but is not a signal of conviction at current prices; absent transcript, management's own view on valuation is opaque

Stanley Druckenmiller — 🟡 watch · 52/100 · medium confidence

RMD presents a mixed picture through the Druckenmiller lens. The fundamental quality is undeniable — $1.65B FCF, 33.4% operating margins, 27% net margins, ROIC of 21% (from fundamentals block) — but the key question for my framework is always DIRECTION, not where things stand today. On that score, the evidence is muddled. Revenue growth is solid but decelerating at the second-derivative level: FY2024 revenue growth was ~10.9% YoY, FY2025 ~9.8%, FY2026 ~9.9% — essentially flat trajectory, not accelerating. FCF actually declined slightly year-over-year in FY2026 ($1.649B vs $1.662B in FY2025 per the history block), which is a second-derivative warning. The tape is clearly broken: stock is down 9.25% over 52 weeks, 15% below 52-week high, and was down 20-30% YTD per the narrative — price action directly contradicts a long thesis requiring confirmation. I never size up when the tape disagrees with the story. The ventilator recall overhang (flagged by UBS as clouding FY27 visibility per the narrative) is exactly the kind of unquantified, open-ended liability that makes directional macro-sized positioning impossible — I cannot define a clean invalidation point when the recall scope and financial reserve are unknown (the 10-K filed 2026-08-13 shows field safety notification accruals jumped from $4.8M to $45.7M, a 9x increase, which is alarming and suggests the liability is material). MatrixCare divestiture execution risk adds another variable that blurs the earnings trajectory. On the positive side: the DCF shows ~27% upside to intrinsic value, the balance sheet is clean (D/E 0.06, $1.47B cash vs $399M LT debt per fundamentals), institutional accumulation is occurring, and the RBC upgrade in September 2026 suggests sentiment may be bottoming. The OSA market remains a durable secular wave — not AI-scale but a genuine demographic tailwind with high compliance moat via AirSense device ecosystems and data connectivity. AI risk: ResMed's connected device data moat and cloud-based patient monitoring (AirView platform) may actually be enhanced by AI-driven adherence optimization and clinical insights, rather than disrupted — this is a mild positive through my secular-winner lens but not a near-term catalyst. The macro/liquidity regime is not specified in the fact base, but falling real rates would be a tailwind for this type of quality compounder. Bottom line: quality franchise, but the tape is broken, the second derivative on earnings is not clearly inflecting upward, and the recall liability creates an unquantifiable invalidation problem. This is a watch, not a conviction pass — I want to see Q4 FY2026 earnings clarity on recall costs, FY27 guidance, and price action confirming a bottom before sizing up.

Key points

• Revenue CAGR of ~10.2% over 3 years is solid but not accelerating — second derivative flat-to-decelerating: FY2024 +10.9%, FY2025 +9.8%, FY2026 +9.9% YoY (fundamentals history block)
• FCF declined slightly in FY2026 to $1.649B from $1.662B in FY2025 — second derivative turning slightly negative on the most important metric (fundamentals history)
• DCF intrinsic value of $298.18/share implies ~27% upside at $235.50 current price; bull case $391 (valuation block) — asymmetry exists IF thesis confirms
• Balance sheet exceptionally clean: D/E 0.06, $1.47B cash, $399M LT debt (fundamentals block); net cash position of ~$1.07B (valuation assumptions)
• Institutional accumulation by State Street, Deutsche Bank, California Teachers noted in narrative — smart money buying into weakness is a positive signal
• Field safety notification accrual surged from $4.8M (June 2025) to $45.7M (June 2026) per 10-K filed 2026-08-13 — 9x increase signals material and growing liability
• RBC upgraded September 2026 after mid-July downgrade (narrative) — analyst sentiment inflecting may be an early tape signal
• OSA market secular growth + connected device/data moat (AirView ecosystem) provides durable multi-year tailwind not easily disrupted by AI

Red flags

• TAPE IS BROKEN: -9.25% over 52 weeks, -15% from 52-week high, reported 20-30% YTD decline in narrative — primary Druckenmiller disqualifier for full conviction sizing
• Ventilator recall scope unquantified: UBS cited as clouding FY27 guidance; no forward guidance available in fact base; cannot define clean invalidation point
• Field safety notification accrual 9x increase ($4.8M to $45.7M per 10-K 2026-08-13) plus masks-with-magnets recall suggests multiple concurrent product liability events
• FCF second derivative negative: FY2025 $1.662B → FY2026 $1.649B; FCF margin compressed from 32.3% to 29.2% (fundamentals history) — heading wrong direction
• MatrixCare divestiture announced July 2026 per narrative — no proceeds, rationale, or earnings impact disclosed; introduces execution uncertainty into near-term financials
• No forward guidance or earnings call transcript in fact base — impossible to assess whether EPS estimate revisions are positive or negative, a critical Druckenmiller input
• CEO insider selling ~$1M August 2026 (narrative) — not conclusive but not a confidence signal from the insider with best information
• $21.7M restructuring charges recorded in nine months ended March 2026 (10-Q filed 2026-05-01) — workforce reductions suggest management sees need to cut costs, not an expansion posture

Benjamin Graham — 🟡 watch · 52/100 · medium confidence

ResMed is a high-quality, profitable, established business with a long track record of earnings stability and strong cash generation — characteristics Graham would respect. However, judged strictly against Graham's quantitative value criteria, the stock falls short of the margin of safety he demanded. The trailing P/E of 22.1x exceeds his defensive ceiling of 15x. The P/B of 5.1x is elevated; the combined P/E × P/B product of roughly 113 far exceeds his threshold of 22.5. The stock is not remotely near net-net territory — net current asset value (current assets $4.325B minus ALL liabilities $2.381B) yields approximately $1.944B, or roughly $13.47 per share against a $235.50 price — so no asset floor protection exists. On the positive side, balance-sheet strength is genuine: current ratio of 3.1x (well above Graham's 2x minimum per the 10-K filed 2026-08-13), long-term debt of only $399M versus working capital of approximately $2.93B — the long-term debt-to-working-capital test passes comfortably. Earnings have been positive and growing every year in the available record (revenue CAGR ~10.2% over three years per fundamentals; net income rising from $779M in FY2022 to $1.523B in FY2026 per fundamentals history). Dividends are paid and were recently increased (per narrative). The DCF intrinsic value is estimated at $298.18/share, implying roughly 27% upside — meaningful but well short of Graham's preferred one-third-or-more discount. At the bear-case DCF of $233.41, the stock is essentially at fair value or slightly below. The earnings yield of 5.8% (per fundamentals) modestly exceeds current high-grade bond yields, providing limited but real earnings-yield support. Field safety notification expenses for masks and Astral devices (per 10-K filed 2026-08-13) and a ventilator recall overhang (per narrative) introduce near-term earnings uncertainty. The Noctrix acquisition ($335M, closed June 2026 per 10-K) adds integration risk. Restructuring charges of $21.7M in the nine months ended March 2026 (per 10-Q filed 2026-05-01) and $64.2M in FY2024 (per 10-K filed 2025-08-08) are modest relative to earnings but signal ongoing operational adjustment. AI disruption is not a primary near-term threat to ResMed's device and software businesses — sleep apnea diagnostics and CPAP therapy require physical hardware and regulatory clearance, though AI could assist competitors in sleep diagnostics over a 5-10 year horizon. The absence of a full earnings call transcript and unclear FY27 guidance (per narrative) limit confidence. In summary: a financially sound, dividend-paying, profitable franchise — but priced for quality at multiples well above what Graham's conservative criteria would sanction. This is a 'watch' at current prices pending a material correction toward the $165-180 range that would offer a genuine one-third discount to conservative intrinsic value.

Key points

• Earnings stability confirmed: net income grew from $779M (FY2022) to $1.523B (FY2026) with no loss years in the available record (fundamentals history).
• Balance sheet passes Graham's key tests: current ratio 3.1x exceeds the 2x minimum; long-term debt of $399M (10-K filed 2026-08-13) is well below working capital of ~$2.93B.
• Dividend paid and recently increased (narrative); signals financial durability Graham would recognize.
• Earnings yield of 5.8% (fundamentals) offers modest spread over investment-grade bond yields — barely adequate by Graham standards.
• DCF base-case intrinsic value $298.18/share implies ~27% upside, but bear case of $233.41 is near current price — insufficient margin of safety by Graham's one-third rule.
• Net-net value (current assets minus ALL liabilities) ~$13.47/share — stock trades at 17x this floor, so no asset-floor protection whatsoever.

Red flags

• P/E of 22.1x exceeds Graham's defensive ceiling of 15x for a defensive investor — requires growth assumption to justify.
• P/B of 5.1x is high; P/E × P/B product ~113 far exceeds Graham's 22.5 composite threshold (fundamentals).
• No margin of safety at current price: DCF bear case ($233.41) is barely below the $235.50 stock price, meaning even modest assumption degradation erases upside (valuation block).
• Field safety notification expenses accrued at $45.7M for masks and Astral devices as of June 2026 (10-K filed 2026-08-13) plus ventilator recall uncertainty (narrative) could impair near-term earnings.
• MatrixCare divestiture scope, proceeds, and earnings impact not detailed in available material (narrative) — creates forecasting uncertainty.
• Noctrix acquisition ($335M, June 2026 per 10-K filed 2026-08-13) is preliminary in purchase price allocation — goodwill and intangible write-down risk not fully known.
• Restructuring charges recorded ($21.7M nine months to March 2026 per 10-Q filed 2026-05-01) suggest ongoing operational instability, though small relative to earnings.

Seth Klarman — 🟡 watch · 52/100 · medium confidence

ResMed presents a genuinely high-quality business — strong FCF generation ($1.65B in FY2026 per fundamentals block), near-pristine balance sheet (net cash positive at approximately $1.07B net debt negative per valuation assumptions, long-term debt only $399M per 10-K filed 2026-08-13), and a dominant franchise in sleep-disordered breathing. The DCF model implies a base intrinsic value of ~$298/share against a current price of $235.50, suggesting roughly 27% upside on the base case. However, from a strict Klarman margin-of-safety lens, several factors prevent a clean 'pass.' First, the DCF's terminal value comprises 79.2% of enterprise value (per the valuation block), meaning the intrinsic value is overwhelmingly dependent on perpetuity assumptions — precisely the kind of single-method, growth-dependent valuation I distrust. The bear-case DCF sensitivity is $233.41, barely below current price of $235.50, meaning there is essentially zero asset-backed or normalized-cash-flow floor that would protect capital in a deterioration scenario. Second, the business is an asset-light, intangible-heavy franchise — goodwill and acquired intangibles are substantial (developed/core product technology gross $396M per 10-Q filed 2026-05-01, customer relationships $484M gross) — so a liquidation or asset-coverage floor is not meaningful. Third, near-term headwinds are real and unquantified: (a) ventilator recall issues flagged by UBS as clouding FY27 per narrative, with accrued field safety notification expenses jumping from $4.8M to $45.7M between June 2025 and June 2026 per 10-K filed 2026-08-13, a nearly 10x increase that signals material remediation costs not yet fully reserved; (b) the MatrixCare divestiture creates execution uncertainty and unknown proceeds/restructuring costs; (c) $21.7M in restructuring charges were taken in the nine months ended March 2026 per 10-Q filed 2026-05-01, suggesting ongoing operational reorganization. Fourth, the valuation at 22x earnings and 20x FCF is not a 'cigar butt' or deeply discounted situation — it is fair-to-modest pricing for a quality compounder, not a genuine margin-of-safety opportunity in the Baupost sense. On the positive side: the balance sheet is genuinely strong (current ratio 3.1x, debt/equity 0.06x per fundamentals; net cash position), FCF conversion is high (29% FCF margin FY2026), ROE and ROIC are solid (23% and 21% respectively), and the stock is 15% below its 52-week high with institutional buyers accumulating. The field safety notification expense surge ($45.7M vs $4.8M prior year) is a specific, documentable concern worth monitoring but may also represent conservative reserving that creates a catalyst if costs come in lower. AI risk is not a near-term moat impairment — the hardware/software ecosystem around CPAP titration and patient compliance monitoring would be difficult to commoditize, though remote diagnostic AI could eventually reduce the role of proprietary ResMed data platforms. Overall: this is a watch, not a pass — the quality is undeniable but the margin of safety is insufficient for a Baupost-style conviction buy. I would wait for either a price closer to the bear-case DCF of ~$233 with greater clarity on the ventilator recall liability, or a more significant dislocation that creates a real downside floor well below current price.

Key points

• Net cash position (~$1.07B net cash per valuation block; long-term debt only $399M per 10-K filed 2026-08-13) provides genuine balance sheet safety — a Klarman prerequisite that is met
• FCF of $1.65B in FY2026 (10-K filed 2026-08-13) and 29% FCF margin demonstrates durable cash generation; FCF/share yield ~4.9% at current price is reasonable but not compelling on an absolute basis
• DCF bear case of $233.41 (valuation block) is barely below current price of $235.50 — there is no meaningful margin of safety in the conservative scenario
• Terminal value = 79.2% of enterprise value (valuation block) — intrinsic value is overwhelmingly growth-dependent, not asset- or normalized-earnings-backed, which is precisely the valuation structure I distrust
• Field safety notification expense accrual surged from $4.8M (June 2025) to $45.7M (June 2026) per 10-K filed 2026-08-13 — a near-10x increase indicating material but still-uncertain recall/remediation liability
• MatrixCare divestiture announced July 2026 (narrative) creates potential for asset realization and portfolio simplification — a genuine catalyst worth monitoring for value unlock
• Institutional accumulation (State Street, Deutsche Bank, CalSTRS per narrative) suggests smart money sees value, but momentum/institutional following is not itself a margin-of-safety argument

Red flags

• Bear-case intrinsic value of $233.41 (valuation block) provides essentially zero downside protection at current price of $235.50 — fails the margin-of-safety test on a conservative scenario
• Terminal value represents 79.2% of total enterprise value (valuation block), making the thesis almost entirely dependent on optimistic perpetuity growth assumptions that cannot be stress-tested from the balance sheet
• Ventilator recall/field safety notification liability is material and growing — $45.7M accrued at June 2026 vs. $4.8M at June 2025 (10-K filed 2026-08-13); scope and total liability remain opaque with no earnings call transcript available
• Intangible-heavy asset base (goodwill implicit in $335M Noctrix acquisition per 10-K filed 2026-08-13, plus ~$484M gross customer relationships, ~$396M gross developed technology per 10-Q filed 2026-05-01) means liquidation value would be a fraction of book value — no hard asset floor
• CEO insider selling (~$1M in August 2026 per narrative) and restructuring charges ($21.7M in nine months ended March 2026 per 10-Q filed 2026-05-01) create noise around management confidence and operational stability
• No earnings call transcript available (narrative explicitly flags this) — cannot assess management candor on recall scope, MatrixCare proceeds, or FY27 guidance, creating information risk that is unacceptable for a high-conviction position

Peter Lynch — 🟡 watch · 52/100 · medium confidence

ResMed is a stalwart-class medical device company — not a fast grower. The one-sentence story is clear: ResMed makes CPAP devices and software for the sleep apnea and respiratory care market, and earns recurring revenue on masks/accessories and software subscriptions. Revenue CAGR of ~10.2% (3-year, per fundamentals) and net income growth from $898M (FY2023) to $1,523M (FY2026) is solid but decelerating at the margin (FY2025 to FY2026 net income grew ~8.7%, per fundamentals history). This is a stalwart, not a fast grower, so I'm judging it on stalwart criteria. The core business is understandable, the balance sheet is genuinely excellent (debt-to-equity 0.06 per fundamentals, $1.47B cash vs $399M long-term debt per 10-K filed 2026-08-13, net cash position of ~$1.07B per valuation block), and FCF conversion is outstanding (FCF margin 29-32% range over FY2024-FY2026 per fundamentals history). However, the PEG is 2.16 (per fundamentals), which is well above my 1.0 threshold — this is the central problem from my lens. Even adjusting for the dividend yield (modest; dividend amount not disclosed in fact base but described as recently raised in narrative), PEG is unlikely to compress below 1.5 given the growth rate. P/E of 22x on ~10% earnings growth is a stalwart paying a growth premium it hasn't fully earned. For a stalwart, I'd want to buy at a 30-50% gain target and sell; at 22x P/E with PEG of 2.16, the entry price feels stretched for the category. On the positive side: balance sheet is nearly pristine, FCF of $1.65B supports buybacks and dividends, operating margin is 33.4% (fundamentals), ROIC is 21.3%, and the OSA market has genuine secular growth. Inventories appear in line — raw materials $351M, finished goods $559M as of March 31, 2026 (10-Q filed 2026-05-01), not growing faster than revenue. Key concerns from my red flags: (1) The Noctrix acquisition ($335M, 10-K filed 2026-08-13) raises mild diworsification concern — wearable therapeutics is adjacent but expensive; (2) Field safety notification expenses for masks-with-magnets ($45.7M accrued at June 30, 2026 vs $4.8M prior year per 10-K) represent a material jump and are a near-term earnings headwind; (3) Ventilator recall issues flagged by UBS (narrative) with unclear financial scope; (4) MatrixCare divestiture (narrative) signals strategic repositioning — could be positive simplification or signals the software segment was a diworsification mistake; (5) Restructuring charges of $21.7M in nine months ended March 31, 2026 (10-Q filed 2026-05-01) add noise. The PEG of 2.16 is simply too high for my comfort as a stalwart. The DCF (intrinsic $298.18 vs $235.50 price, 26.6% upside) is supportive, but I don't put as much weight on DCF modeling — I care about the PEG and the earnings story. AI/disruption angle: AI could enhance ResMed's connected device ecosystem and data analytics platform (AirView/myAir), which are embedded in the care pathway and create switching costs. However, AI could also enable lower-cost competitors to challenge mask/device design and software platforms over a 5-10 year horizon. Net assessment: modest enhancement, not existential threat in the medium term. Overall: a high-quality stalwart at a stalwart-unfriendly multiple, with near-term noise from recalls and divestitures. I'd watch at current prices and revisit if the PEG compresses toward 1.3-1.5x on earnings growth acceleration or price weakness.

Key points

• Stalwart categorization: ~10% revenue CAGR, 33% operating margins, 21% ROIC — high-quality but not a fast grower
• Balance sheet nearly pristine: debt-to-equity 0.06, net cash ~$1.07B, long-term debt only $399M (10-K filed 2026-08-13)
• FCF generation is exceptional: $1.65B in FY2026, FCF margin ~29-32% for three consecutive years (fundamentals history)
• OSA market is a genuine secular growth driver — underdiagnosed population, recurring consumable revenue (masks/accessories) creates annuity-like revenue
• Inventories not piling up: raw materials $351M, finished goods $559M (10-Q filed 2026-05-01), consistent with prior period
• DCF suggests 26.6% upside to intrinsic value of $298.18, providing some margin of safety
• Institutional accumulation noted (State Street, CalSTRS, Deutsche Bank per narrative) — though this reduces the neglected-stock edge

Red flags

• PEG of 2.16 (fundamentals) — more than double my 1.0 threshold; stalwart priced at a growth premium it has not fully earned
• Field safety notification accrual jumped from $4.8M to $45.7M year-over-year (10-K filed 2026-08-13) — masks-with-magnets and Astral recall headwinds are material
• Ventilator recall flagged by UBS as clouding FY27 guidance (narrative); financial scope not disclosed in available filings — unknown liability
• Noctrix acquisition for $335M (10-K filed 2026-08-13) into wearable therapeutics — mild diworsification risk; purchase price allocation still preliminary
• Restructuring charges of $21.7M in nine months ended March 31, 2026 (10-Q filed 2026-05-01) following $64M in FY2024 — recurring restructuring is a yellow flag
• MatrixCare divestiture announced July 2026 (narrative): strategic rationale and proceeds unknown; suggests prior acquisition may have been a diworsification
• No earnings call transcript available — cannot assess management candor on recall scope, FY27 guidance, or FCF trajectory post-divestiture

Paul Singer — 🟡 watch · 52/100 · medium confidence

ResMed is a high-quality, single-segment-dominant medical device company with genuine operating excellence — 33% operating margins, ~29% FCF margins, ROIC of 21%, and a nearly debt-free balance sheet (net cash of ~$1.07B per the DCF assumptions). This is NOT a classic Elliott activist target: there is no conglomerate discount to arbitrage, no obvious governance entrenchment, no hoarded cash rotting on the balance sheet, and no chronic underperformer with defensible assets being mismanaged. However, the fact base reveals a narrow but real self-help angle that warrants a 'watch' rather than full abstention or a pass. The key tension: RMD has a two-segment structure (Sleep and Breathing Health plus Residential Care Software) where the software segment (Residential Care Software) has been a capital sink — the 10-K filings document repeated operating lease right-of-use asset impairments in the RCS segment ($4.1M in FY2024, $2.7M in each of the two quarters of FY2026 reported), and the narrative explicitly flags the MatrixCare divestiture as announced July 2026. This is self-help already partially in motion — management is shedding the software drag — which partially closes the gap before any external pressure. The capital allocation record is mixed: the company burned through ~$1.4B in long-term debt from FY2023 ($1.435B) to FY2026 ($399M), which is shareholder-friendly deleveraging, but also acquired Noctrix Health for $335M (closed June 1, 2026, per the 10-K) and completed VirtuOx (FY2025), signaling continued M&A appetite with returns not yet assessable. FCF nearly tripled from FY2022 ($216M) to FY2025 ($1.66B), so recent capital allocation on the debt side earns credit. The DCF suggests ~27% upside to intrinsic value ($298 base vs. $235.50 price), which provides a reasonable margin of safety — the bear case of $233.41 is essentially at the current price, meaning the downside floor is thin if the ventilator recall and FY27 guidance disappoint. The governance angle is limited: RMD is incorporated in Delaware, appears to have a standard board (no dual-class, no founder super-majority flagged in the filings), and the MatrixCare sale signals that management is already responding to pressure — reducing the activist lever. The field safety notification accrual jump ($4.8M to $45.7M for the Astral recall, per 10-K Note 7) is a meaningful incremental liability that clouds near-term earnings and could suppress the stock further, providing a potential entry point. The sum-of-parts angle is narrowing fast: with MatrixCare being sold, the remaining business is essentially a pure-play sleep/respiratory device and connected health platform — a cleaner story, less activist fodder. The primary residual self-help gap is: (1) pace of capital return — $1.47B cash on hand with only $399M long-term debt; management could accelerate buybacks at current prices well below intrinsic value; and (2) clarity on ventilator recall liability. Neither of these requires Elliott-style board confrontation. The company is already doing the right things, just perhaps slower than an activist would demand. This is a 'watch' situation: monitor whether the MatrixCare proceeds are deployed wisely, whether the Noctrix and VirtuOx acquisitions earn their cost of capital, and whether management accelerates buybacks. Not a compelling activist target but a value-aware position if the stock dips further on recall headlines.

Key points

• Self-help partially in motion: MatrixCare (Residential Care Software segment) divestiture announced July 2026 — management already eliminating the underperforming segment before external pressure, which closes the activist angle but confirms value destruction was real
• Net cash position of ~$1.07B (per DCF) with only $399M long-term debt (10-K FY2026) and $1.47B cash — significant balance sheet slack that could support accelerated buybacks at current price ~15% below 52-week high
• FCF compounded from $216M (FY2022) to $1.65B (FY2026) per the fundamentals history — genuine cash engine that provides a real downside floor independent of any activist outcome
• Two-stage DCF intrinsic value of $298/share (27% upside) with bear case of $233 essentially at current price — margin of safety exists but is not wide; bear case offers minimal protection
• Noctrix acquisition ($335M, closed June 2026, per 10-K Note 18) is recent and unproven — returns cannot yet be assessed; represents ongoing M&A appetite that could dilute buyback capacity
• Astral field safety notification accrual jumped from $4.8M to $45.7M (10-K Note 7, FY2026 vs. FY2025) — a material incremental liability creating near-term earnings overhang and potential stock dislocation opportunity
• ROIC of 21.3% and operating margin of 33.4% suggest the core Sleep and Breathing Health business is already run near its optimal configuration — limits the 'new owner would do better' argument
• No dual-class structure, poison pill, or founder control flagged in filings — standard Delaware corporation with annually elected board presumed, meaning a lever exists if needed but is unlikely to be required given management's self-correction

Red flags

• Gap is real but substantially closing without external pressure — MatrixCare sale, debt repayment, and dividend increase all signal management responsiveness; activist lever has diminishing value
• No downside floor independence: DCF bear case ($233) is nearly at current price ($235.50), meaning if ventilator recall scope expands or FY27 guidance disappoints materially, there is limited tangible asset protection
• Ventilator recall scope unclear: Astral FSN accrual of $45.7M (10-K) and narrative reference to UBS flagging FY27 guidance clouds — financial exposure not fully quantified in available material
• Noctrix ($335M) and VirtuOx acquisitions still unproven — ongoing M&A spend before prior deals are validated is a capital allocation red flag; returns cannot be assessed from available filings
• CEO sold ~$1M in stock August 2026 (per narrative) — not dispositive but lacks a confidence signal at a time when management should be buying
• MatrixCare divestiture terms, proceeds, and buyer not disclosed in available material — cannot assess whether proceeds will be returned to shareholders or recycled into further acquisitions
• No earnings call transcript available — cannot assess management's candor on recall liability, guidance, or capital return commitment; this is a material evidence gap for any activist sizing decision
• AI/disruption risk: ResMed's connected health platform (AirSense devices, myAir app, data analytics) could face commoditization pressure if AI-driven sleep diagnostics lower barriers to entry or if GLP-1 weight-loss drugs (semaglutide etc.) structurally reduce the OSA patient pool — this is a genuine long-term demand risk not addressable through activist intervention

Walter Schloss — 🔴 avoid · 28/100 · high confidence

ResMed is a high-quality compounder but it is emphatically not a Schloss bargain. My discipline requires cheapness anchored in tangible book value and a price beaten down to multi-year lows with a hard-asset margin of safety. RMD fails nearly every criterion I care about. Price-to-book is 5.1x per the fundamentals block, and because goodwill and acquired intangibles dominate the asset base, tangible book is a fraction of that already-rich stated book. The 10-K (filed 2026-08-13) shows total stockholders' equity of $6.585 billion against total assets of $8.966 billion and total liabilities of $2.381 billion. But within those assets sit substantial acquired intangible assets — the 10-Q (filed 2026-05-01) alone shows developed/core product technology of $396 million gross and customer relationships of $485 million gross, plus goodwill (not separately excerpted in full but implied by the acquisition history including the $335 million Noctrix acquisition closed June 1, 2026 per the 10-K). Strip out goodwill and acquired intangibles and tangible book is a deeply negative or negligible figure, meaning the stock trades at an enormous multiple of any asset base I can actually appraise. Price-to-sales is 5.94x and P/E is 22x — not cheap by any absolute measure. The stock sits 15% below its 52-week high of $277.67 and is only modestly below its range; it is not anywhere near a multi-year beaten-down low by Schloss standards. The balance sheet has improved dramatically — long-term debt fell from $1.435 billion (June 2023, per the 10-K filed 2024-08-09) to $399 million (June 2026, per the 10-K filed 2026-08-13) — but debt reduction does not make a rich stock cheap. Working capital is solid (current ratio 3.1x per fundamentals) and FCF is genuine at $1.65 billion for FY2026, but strong cash generation belongs in a quality/compounder frame, not a Schloss asset-value frame. The investment thesis for RMD lives entirely in earnings power, brand, regulatory positioning, and recurring revenue from the OSA/SDB device ecosystem — none of which I can appraise from tangible assets on the balance sheet. Insider selling (CEO sold ~$1M per the narrative) is a mild negative signal, though not alarming. The dividend exists but the payout is modest relative to valuation. The business is complex — two reporting segments, software (Residential Care Software), wearable therapeutics (Noctrix acquisition), device leasing, and international operations with hedging instruments — which I would typically find difficult to evaluate from filings alone. Field safety notification liabilities (masks with magnets: $45.7M accrued at June 2026 per the 10-K; Astral device recall: also present) and the MatrixCare divestiture add operational complexity. The DCF shows $298 intrinsic value vs. $235.50 price — a 27% upside — but that is a growth-and-earnings-power model, not a Schloss asset appraisal. I cannot verify or use it. This is a fine business; it is simply not my kind of opportunity.

Key points

• Price-to-book of 5.1x (fundamentals block); tangible book likely negative or negligible after stripping goodwill and acquired intangibles including $396M gross product technology and $485M gross customer relationships (10-Q, 2026-05-01)
• Stock is only 15% below 52-week high of $277.67 — not a beaten-down, out-of-favor name by any Schloss standard
• Long-term debt reduced materially from $1.435B (June 2023) to $399M (June 2026) per 10-K filings — balance sheet improved but does not make valuation cheap
• FCF of $1.65B and operating margin of 33% reflect earnings power, not tangible asset value — the thesis is a compounder thesis, not an asset-value thesis
• Current ratio of 3.1x and net cash position of ~$1.07B (valuation block net debt figure) are genuine positives but insufficient to offset the valuation premium
• Dividend exists but payout is modest relative to market cap; does not signal the kind of distressed asset value I look for

Red flags

• Price-to-book 5.1x; tangible book almost certainly deeply negative given scale of acquired intangibles and goodwill from multiple acquisitions including $335M Noctrix (10-K, 2026-08-13)
• Thesis depends entirely on earnings power, recurring device revenue, and software — not verifiable hard assets; exactly the kind of intangible-heavy story I avoid
• Stock trading near 52-week highs range, not at multi-year lows; no price dislocation of the kind that generates Schloss-style margin of safety
• CEO insider selling noted in narrative (~$1M August 2026); no evidence of meaningful insider buying
• Business complexity: two segments, international hedging, equity investment portfolio with recurring mark-to-market losses (net unrealized losses of $15M in FY2026 per 10-K), device leases, software, recalls — hard to appraise from filings alone
• Field safety notification accruals ($45.7M for masks with magnets at June 2026, plus Astral recall per 10-K) and ventilator recall overhang (per narrative, UBS flagged) add unquantified liability

---

Fact base appendix

Price

• last_close: 235.5
• as_of: 2026-10-19
• high_52w: 277.67
• low_52w: 180.265
• range_source: provider
• pct_below_52w_high: -15.19
• return_1d_pct: -1.45
• return_52w_pct: -9.25

Fundamentals

• last_price: 235.5
• market_cap: 33608561389
• fifty_two_week_high: 277.67
• fifty_two_week_low: 180.265
• beta: 0.7689212
• currency: USD
• exchange: NEW YORK STOCK EXCHANGE, INC.
• sector: Health Care
• industry: Health Care
• price_source: finnhub
• bars: 1
• entity: ResMed Inc.
• fiscal_year: 2026
• revenue: 5653443000
• revenue_period: 2026-06-30
• net_income: 1523000000
• net_income_period: 2026-06-30
• operating_income: 1886715000
• operating_income_period: 2026-06-30
• operating_cash_flow: 1805829000
• operating_cash_flow_period: 2026-06-30
• capex: 156285000
• capex_period: 2026-06-30
• total_assets: 8965950000
• total_assets_period: 2026-06-30
• total_liabilities: 2380557000
• total_liabilities_period: 2026-06-30
• current_assets: 4324739000
• current_assets_period: 2026-06-30
• current_liabilities: 1395110000
• current_liabilities_period: 2026-06-30
• stockholders_equity: 6585393000
• stockholders_equity_period: 2026-06-30
• cash_and_equivalents: 1469234000
• cash_and_equivalents_period: 2026-06-30
• long_term_debt: 399415000
• long_term_debt_period: 2026-06-30
• shares_outstanding: 144252306.0
• shares_wad: 145723000.0
• shares_wad_annual: 146054000.0
• operating_margin: 0.3337
• net_margin: 0.2694
• roe: 0.2313
• debt_to_equity: 0.0607
• current_ratio: 3.0999
• roic: 0.2134
• free_cash_flow: 1649544000
• fcf_margin: 0.2918
• pe_ratio: 22.07
• price_to_fcf: 20.37
• price_to_sales: 5.94
• revenue_cagr: 0.1021
• revenue_cagr_years: 3
• fundamentals_source: edgar_companyfacts
• market_cap_source: vendor_corroborated
• price_to_book: 5.1
• earnings_yield: 0.058
• peg: 2.16

Filings reviewed

• 8-K (2026-09-01) https://www.sec.gov/Archives/edgar/data/943819/000119312526378487/d530283d8k.htm
• 8-K (2026-08-17) https://www.sec.gov/Archives/edgar/data/943819/000119312526354154/d292919d8k.htm
• 10-K (2026-08-13) https://www.sec.gov/Archives/edgar/data/943819/000094381926000047/rmd-20260630.htm
• 8-K (2026-08-06) https://www.sec.gov/Archives/edgar/data/943819/000119312526337962/d158732d8k.htm
• 8-K (2026-07-07) https://www.sec.gov/Archives/edgar/data/943819/000119312526297658/d88958d8k.htm
• 10-Q (2026-05-01) https://www.sec.gov/Archives/edgar/data/943819/000094381926000025/rmd-20260331.htm
• 8-K (2026-04-30) https://www.sec.gov/Archives/edgar/data/943819/000119312526197282/d50610d8k.htm
• 8-K (2026-04-30) https://www.sec.gov/Archives/edgar/data/943819/000119312526197192/d146862d8k.htm
• 10-Q (2026-01-30) https://www.sec.gov/Archives/edgar/data/943819/000094381926000007/rmd-20251231.htm
• 10-K (2025-08-08) https://www.sec.gov/Archives/edgar/data/943819/000094381925000035/rmd-20250630.htm
• 10-K (2024-08-09) https://www.sec.gov/Archives/edgar/data/943819/000094381924000013/rmd-20240630.htm

Other sources

• [news] ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
• [news] ResMed Inc. $RMD Shares Purchased by State Street Corp - MarketBeat
• [news] ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
• [news] ResMed Stock Is Down 30% From Its Peak While Free Cash Flow Just Hit a Record $1.7 Billion - TIKR.com
• [news] ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
• [news] Deutsche Bank AG Takes Position in ResMed Inc. $RMD - MarketBeat
• [news] Why ResMed (RMD) Shares Are Falling Today - Yahoo Finance
• [news] ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
• [news] ResMed Inc (NYSE:RMD) Offers a Quality Dividend Built on Strong Profitability and Financial Health - ChartMill
• [news] ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
• [news] Is ResMed Inc (RMD) a Bargain After 6.3% Drop? GF Value Says Und - GuruFocus
• [news] ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
• [news] ResMed stock held at Hold by Needham as MatrixCare sale announced - Investing.com
• [news] ResMed Inc (NYSE:RMD) Builds on a Quality Foundation with Strong Profitability and Cash Conversion - ChartMill
• [news] ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
• [news] Michael Farrell proposes selling 4,991 ResMed (NYSE: RMD) shares through Fidelity. - Stock Titan
• [news] ResMed (NYSE:RMD) Offers Dividend Investors a Sustainable Payout Built on Quality Fundamentals - ChartMill
• [news] ResMed (NYSE: RMD) counsel surrenders shares for RSU tax withholding - Stock Titan
• [news] Is It Too Late to Buy ResMed Inc (RMD) After 3.2% Rally? GF Value Says Undervalued - GuruFocus
• [news] ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
• [news] ResMed (RMD) Stock Looks Cheap Even As The Market Stays Cautious - Yahoo Finance
• [news] ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
• [news] Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026 - Moomoo
• [news] ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
• [news] ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
• [news] BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD) - TradingView
• [news] ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says - Yahoo Finance
• [news] Resmed Inc Stock (RMD) Moved Up by 3.05% on Sep 15: A Full Analysis - TradingKey
• [news] Is This the Right Time to Retain Resmed Stock in Your Portfolio? - TradingView
• [news] ResMed stock upgraded at RBC Capital Markets (RMD:NYSE) - Seeking Alpha
• [news] ResMed Inc. $RMD Shares Sold by Corient Private Wealth LP - MarketBeat
• [news] California State Teachers Retirement System Increases Holdings in ResMed Inc. $RMD - MarketBeat
• [news] Is This the Right Time to Retain Resmed Stock in Your Portfolio? - Yahoo Finance
• [news] ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
• [news] ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
• [news] Insider Selling: ResMed (NYSE:RMD) CEO Sells $1,026,598.79 in Stock - marketbeat.com
• [news] Assenagon Asset Management S.A. Grows Stock Holdings in ResMed Inc. $RMD - marketbeat.com
• [news] ResMed (NYSE: RMD) CEO sells 4,991 shares after option exercise - Stock Titan
• [news] Is This the Right Time to Retain Resmed Stock in Your Portfolio? - TradingView
• [news] ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
• [news] ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
• [news] ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
• [news] ResMed Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
• [news] ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
• [news] ResMed Stock is Down 20% in 2026. Is It a Buying Opportunity or a Warning Sign? - TIKR.com
• [news] Is ResMed Inc. (RMD) Stock Still a Long-Term Winner as OSA Market Expansion Continues? - Yahoo Finance
• [news] ResMed Inc. (RMD) Stock forecasts - Yahoo Finance UK
• [news] 350,860 Shares in ResMed Inc. $RMD Acquired by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
• [news] ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
• [news] Precision Trading with Resmed Inc. (RMD) Risk Zones - Stock Traders Daily
• [news] ResMed stock downgraded at RBC Capital Markets (RMD:NYSE) - Seeking Alpha
• [news] ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
• [news] ResMed (NYSE:RMD) Stock Forecast & Analyst Predictions - Simply Wall Street
• [news] ResMed’s Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
• [news] ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
• [news] Handelsbanken Fonder AB Raises Stock Position in ResMed Inc. $RMD - marketbeat.com
• [news] ResMed Inc. Stock 12‑Month Price Target Cut to $258.47, Implies 14% Upside - TradingView
• [news] How Investors May Respond To ResMed (RMD) Dividend Hike And Ventilator Recall Headwinds - Sahm
• [news] Is ResMed Inc. (RMD) A Good Stock To Buy Now? - Yahoo Finance
• [news] Is ResMed Stock Underperforming the Dow? - Yahoo Finance
• [news] ResMed (NYSE:RMD) Stock: Insider Michael Farrell Sells 4,991 Shares - MarketBeat
• [news] ResMed chairman & CEO Michael Farrell sells $1.1m in shares - Investing.com
• [news] ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
• [news] ResMed (RMD) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
• [news] ResMed (NYSE:RMD) Q4 Results Inline with Estimates; Stock Slips 1.9% - ChartMill
• [news] Is ResMed Inc (RMD) Undervalued After Q4 Earnings Miss? EPS at $ - GuruFocus
• [news] Earnings Flash (RMD) Resmed Inc. Reports Q4 Revenue $1.46B, vs. FactSet Est of $1.46B - marketscreener.com
• [news] ResMed Inc. (NYSE: RMD) grows FY 2026 revenue to $5,653M and lifts dividend - Stock Titan
• [news] Resmed raises quarterly dividend 10% to $0.66 per share - Stock Titan
• [news] Lazard Asset Management LLC Has $734,000 Stock Position in ResMed Inc. $RMD - MarketBeat
• [news] ResMed Inc (RMD) Shares Surge 4.2% -- What GF Score of 90 Tells Investors - GuruFocus
• [news] ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
• [news] Resmed Inc (RMD) Q1 2024 Earnings Report - Results, Call & Slides - TipRanks
• [news] Vista Investment Management Invests $920,000 in ResMed Inc. $RMD - MarketBeat
• [news] 78,381 Shares in ResMed Inc. $RMD Purchased by Quantbot Technologies LP - MarketBeat
• [news] ResMed Inc. (RMD) Stock Forecasts - Yahoo! Finance Canada
• [news] 87,722 Shares in ResMed Inc. $RMD Purchased by Avalon Trust Co - MarketBeat
• [news] 41,381 Shares in ResMed Inc. $RMD Acquired by ABN AMRO Bank N.V. - MarketBeat
• [news] ResMed (RMD) Stock Valuation Check After Mixed Returns And Undervaluation Signals - Yahoo Finance
• [news] Here's What Analysts Are Forecasting For ResMed Inc. (NYSE:RMD) After Its Full-Year Results - simplywall.st

Data gaps

• Dataset completeness: 80 of 80 source documents were dropped to fit the prompt budget — the council did not see them; only 5 of 11 filing excerpts contained readable filing text.

---

Generated 2026-10-19T09:35:13 · est. cost $1.03